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Many engineered nanomaterials (NMs) are being synthesized and explored for 
potential use in consumer and medical products. Already, nanoparticles (NPs) of 
titanium dioxide (TiO2), zinc oxide (ZnO), silver (Ag) and other metals or their oxides 
are present in commercial products such as sunscreens, cosmetics, wound dressings, 
surgical tools, detergents, automotive paints and tires. More recent and advanced 
FDA-approved use of NPs includes quantum dots (QDs) in live cell imaging, 
zirconium oxides in bone replacement and prosthetic devices and nanocarriers in drug 
delivery. The benefits from nanotechnology are aplenty, comprising antimicrobial 
activities, scratch- and water-resistance, long-lasting shine, improved processor 
speeds and better display resolution, to name a few.  
 In the following chapters, we explore the use of NPs in the field of drug 
delivery, especially in cancer. Conventional drugs are governed by Absorption, 
Distribution, Metabolism and Excretion (ADME) and these dictates concentrations, 
kinetics and performance of a drug. Often, simple issues like poor solubility, stability, 
high metabolism and toxicity can prevent a New Chemical Entity (NCE) from 
reaching the market in the long and arduous process of drug discovery. Cleverly 
designed functional NPs can avoid these issues and aid in the development of more 
successful NCEs. 
 Cancer is a disease which involves unregulated cell growth. Treatment 
methods include surgery, radiation therapy and alternative medicine. Newer methods 
developed in recent years also include employing ultrasound, laser and heat. However, 
the most common and easiest method is chemotherapy. Chemotherapeutic drugs kill 
cancer cells which are dividing rapidly but in the process, also harm normal cells and 
could result in serious side effects. Targeted drug delivery vehicles can help overcome 
 x 
 
toxicity by delivering the drug to the target of interest. NPs emerge as a useful 
delivery vehicle for poorly soluble drugs and at the same time, also exhibit targeting 
properties. Abraxane (albumin-bound paclitaxel) was the first particulate drug to be 
approved by the US-FDA in 2005. 
In Chapter 1, a detailed introduction was given to discuss the current issues 
and problems faced by chemists during drug development. Nanotechnology offers an 
attractive solution and the advantages and disadvantages will be discussed. A review 
of current literature explores the mechanisms and success stories of using NPs, 
followed by the rationale of this study. Chapter 2 contains the detailed experimental 
procedures for the studies carried out. 
Interaction of nanoparticles with human cells is an interesting topic for 
understanding toxicity and developing potential drug candidates. In Chapter 3, water 
soluble platinum nanoparticles (Pt-nps) were synthesized via reduction of 
hexachloroplatinic acid using sodium borohydride in the presence of capping agents. 
A thorough characterization was carried out before in vitro studies in human cell lines 
(HeLa, MCF7, HepG2 and IMR90). The toxicity of Pt-nps, combined with the 
possibility to incorporate functional organic molecules as capping agents, meant that 
Pt-nps were suitable for developing new drug candidates. 
In Chapter 4, zebrafish (Danio rerio) was used as an in vivo model which 
developed liver cancer. Designed Pt-nps which target the liver was used for treatment 
of liver cancer. The liver size of Pt-nps treated fish larvae were compared against 
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 The word “nano”, derived from Greek, means “dwarf” and represents one-
billionth of a unit. The oldest and most famous example of nanotechnology is 
probably the Lycurgus Cup that was made in the 5
th
 century B.C. (Daniel and Astruc 
2004). The cup is ruby red in transmitted light and green in reflected light due to the 
presence of gold and silver colloids. The cup’s composition is an alloy of 70 nm 
nanoparticles (NPs) containing 70% silver and 30% gold. Soluble gold was used in 
the Middle Ages because of its curative powers for diseases such as heart and 
venereal problems, dysentery, epilepsy, tumours and for diagnosis of syphilis. Modern 
nanotechnology started in 1959, where physicist Richard P. Feynman championed the 
arrival of nanotechnology (Arvizo, Bhattacharyya et al. 2012). In his famous lecture 
to the American Physical Society at Caltech, he said, “There’s plenty of room at the 
bottom”, hinting at the potential for nanoscale design to influence a wide range of 
fields such as optics and electronics. 
Nanotechnology has enormous potential to affect the society. In 2007, US$60 
billion worth of nanotechnology-incorporated products were sold and this figure rose 
to US$150 billion in 2008 (Scholars). Global research and development is anticipated 
to lead to new medical treatments and tools; more efficient energy production, storage 
and transmission; better access to clean water; more effective pollution reduction and 
prevention; and stronger, lighter materials. It is expected that the sale of products 
employing nanotechnology may reach US$1 trillion per year by 2015 (Xia, Li et al. 
2009), with medical-related products alone occupying US$53 billion in this market 





incorporated products marketed by 587 companies in 30 countries (Scholars ; Xia, Li 
et al. 2009). 
 
Figure 1.1:  The Lycurgus Cup (
©
 Trustees of the British Museum) in reflected (left) 
and transmitted (right) light, displaying the dichroic effect (Daniel and Astruc 2004).  
 
1.2 Classification and synthesis of nanomaterials 
Nanomaterials (NMs) are mainly classified based on their composition and 
shape (Huczko 2000; Rodriguez-Hernandez, Checot et al. 2005; Wang and Cao 2006; 
Byrappa and Adschiri 2007; Hussain, Braydich-Stolle et al. 2009). A few examples 
would include NPs, nanowires, nanotubes, nanofibers and nanohydrogels. The most 
commonly synthesized are NPs owing to their versatility in terms of shapes, sizes, 
functionalities and compositions. Based on composition, NPs can be grouped into the 
following categories: 
1. Organic NMs (polymers, polymeric micelles, dendrimers); 





3. Carbon-rich NMs (carbon nanotubes (CNTs), C60); 
4. Liposome NMs (generally used for drug delivery); 
5. Biological NMs (proteins, lipids, carbohydrates); 
6. Inorganic NMs (Ag, Au, Pt, Fe, TiO2, CaCO3, QDs, silica). 
NPs can be synthesized by using either (Wiley, Sun et al. 2007; Zhou, Ralston et al. 
2009; Misra and Sahoo 2010): 
1. a “top-down” approach, where bulk materials are broken down to 
nanometre scale by milling, grinding, etching and pyrolysis; or 
2. a “bottom-up” approach, which creates nano-objects by combining atomic 
scale materials (Figure 1.2). 
In the top-down approach, a suitable starting material is reduced in size using 
mechanical or chemical methods. Silicon micro-fabrication and photolithography are 
two processes often prepared using the top-down approach (Mishra, Patel et al. 2010). 
An advantage of this method is the possibility of mass production in the industrial 
setting. The major disadvantages of the top-down approach include lengthy, time 
consuming processes, generation of a broad feature size distribution and 
imperfections or defects of the surface morphology generated. Surface deformations 
can have a significant impact on its physical properties and surface chemistry of the 
NPs (Thakkar, Mhatre et al. 2010). In pyrolysis, an organic precursor is burnt after 
forcing through an orifice at high pressure. The resulting ash is processed in order to 
recover the oxidized NPs which have a wide particle size distribution (Thakkar, 
Mhatre et al. 2010). This process consumes enormous amounts of energy to sustain 
the high pressure and temperature. On the contrary, the bottom-up method operates 






Figure 1.2: Nanoparticles of different sizes and morphologies can be synthesized via 
top-down mechanical methods or a bottom-up approach using metal salts (Teow, 
Asharani et al. 2011). 
 
A variety of bottom-up approaches exist, comprising complex coacervation of 
two oppositely-charged polyelectrolytes, co-precipitation, salting-out from an 
aqueous–organic mixture, nanoprecipitation or solvent displacement, solvent 
emulsification–diffusion using an oil–water emulsion and using supercritical fluids. 
These techniques can be used to generate a variety of NMs including liposomes, 
nanoemulsions, polymeric micelles, polymeric NPs, protein NPs, solid lipid NPs and 
carbohydrate (chitosan, alginate, hyaluronic acid, dextran) NPs (Liu, Jiao et al. 2008; 





chemical reduction of metal ions using a suitable reducing agent in the presence of 
stabilizing or capping agent(s). The metal ions are reduced to yield corresponding 
metal atoms that aggregate to form a metal particle. The growth of the metal particle 
is inhibited by the addition of capping agents. The capping agent works either by 
conferring a charge (carboxylic acids and amines) on the surface which helps repel 
neighbouring NPs, or by sterically preventing the agglomeration of two NPs (Thanh 
and Green 2010). Apart from preventing NPs from precipitation, capping agents also 
serve other important functions such as controlling particle size, shape, charge and 
surface functionality which can confer special properties and which behave differently 
from their bulk materials (Liang, Lin et al. 2010). 
Recently, there has been a growing interest in biological synthesis of metallic 
NPs using bacteria (Reddy, Chen et al. 2010), yeast (Kowshik, Ashtaputre et al. 2003), 
fungi, plants and algae (Thakkar, Mhatre et al. 2010). Such methods offer advantages 
over conventional chemical methods which avoid the use of toxic organic solvents 
and reagents, generation of hazardous side-products, high cost and energy 
consumption as well as producing NPs which are relatively non-toxic and 
biocompatible. Different NPs from Ag, Au, CdS, magnetite and uranium were made 
using biological processes (Nanda and Saravanan 2009). A similar method has been 
used in the synthesis of Ag NPs using fungal cell filtrate (Gajbhiye, Kesharwani et al. 
2009). 
 
1.3 Development of nanomaterials  
Nanotechnology has captured both the commercial and academic research 
interests. According to Nel et al., it is expected to advance in four phases (Nel, Xia et 





for specific applications such as for use in sunscreens, wound dressings and other 
commercial products. The success and advancement of the first phase offers many 
promising future opportunities. The second phase relies on active NMs that can 
perform multiple tasks (e.g., biodevices and multifunctional drug delivery systems). 
The third phase will comprise nanosystems with a large number of interacting 
components acting together in a robotic manner, while the fourth and final phase will 
open up more complex systems that can function like living systems in a coordinated 
hierarchical way to provide better understanding of the processes under study. 
Indeed, the applications of nanotechnology in modern day products are aplenty, 
especially from the first and second phase. The term “nano” has been used widely and 
even unrelated products such as “iPod nano” and “Tata Nano” have adopted this word 
in their names (Asharani 2009). NPs, especially, are being commercialised at a fast 
pace. Titanium dioxide NPs are being incorporated in sunscreen lotions to provide 
protection against harmful UV-rays. Gold NPs and nanorods are investigated for the 
diagnosis and treatment of cancer (Boisselier and Astruc 2009). Silver NPs, owing to 
their broad spectrum antimicrobial actions, are widely used in antiseptics, wound 
dressings, components in food containers, detergents, cosmetics and in many other 
consumer products (Edwards-Jones 2009; Rai, Yadav et al. 2009). Polymeric NPs are 
used as nanocarriers transport therapeutic agents directly to the target site with high 
efficiency (Mandal and Kundu 2009). CNTs can be used in electronics due to their 
excellent conductivity (Kang, Kocabas et al. 2007). Medicine is one of the areas 
where extensive research is ongoing for development of better therapeutics. 
Approximately 160 nanodrugs are currently in market with many more in clinical 
trials (Peer, Karp et al. 2007). Nanotechnology has also attracted the defence force, 





developed. NASA is actively developing NPs-based systems in their space shuttles for 
better performance (Asharani 2009). 
 
1.4 Factors affecting biological properties of nanomaterials 
1.4.1 Morphology (size and shape) 
The small size of NMs has created opportunities for them to interact with 
biological entities such as cells, cellular components, bacteria and viruses which are 
never possible at the bulk scale. Cells were found to internalize NMs in a size-
dependant manner, where smaller NPs were found to be better taken up and more 
toxic (Pan, Neuss et al. 2007; He, Zhang et al. 2009), but with a few exceptions 
(Waters, Masiello et al. 2009). In terms of in vivo uptake, 1.4 nm Au NPs were found 
to be able to translocate the air–blood barrier in the rat lung, while 18 nm Au NPs 
were trapped by the lungs and did not enter the blood (Semmler-Behnke, Kreyling et 
al. 2008). Researchers have made use of such properties to design and develop drugs, 
drug carriers (Kim, Jang et al. 2010), anti-cancer agents (Kim, Rozhkova et al. 2010) 
and stains for cell imaging (Mang, Won et al. 2009). 
Examples of metallic NMs include Au NPs, Au nanorods (Leonov, Zheng et al. 
2008), Au nanoplates (triangles, pentagons, hexagons) (Das, Das et al. 2010), FePt 
stars (Pazos-Perez, Rodriguez-Gonzalez et al. 2010), FePt yolk–shell NPs (Gao, Liang 
et al. 2008), Pt cubes, Pt polypods, Pt raspberries (Lim, Ojea-Jimenez et al. 2010), Pt 
nanodendrites (Wang, Wang et al. 2010), Pt nanowires and Pt–MWCNT composites 
(Chen and Holt-Hindle 2010), to name a few (Figure 1.3). Even though NMs with 
different morphologies may find different applications, spherical NPs are the most 
studied NMs. The shapes of Pt NPs were also found to cause a variation in their 





nanoflowers showed the highest reactive oxygen species (ROS)-generating capacity 






Figure 1.3: Morphological variants of inorganic NMs. Platinum NPs with random 
shapes (a), platinum multipods (b), titanium dioxide nanotriangles (c), gold 




1.4.2 Surface functionalization 
Surface functionalization confers stability and interesting properties such as 
surface charges, hydrophilicity or hydrophobicity to NPs. This has an effect on 
biocompatibility, subsequent uptake and downstream processing by cells. Cationic 
NPs enter cells more efficiently than neutral or anionic NPs (Thevenot, Cho et al. 
2008). Secondly, the capping agent can influence solubility and stability of NPs in a 
solvent. Water-soluble molecules (e.g. poly(ethylene glycol)) are frequently used as 
capping agent which offers various advantages, including water solubility, increased 
blood circulation time, decreased enzymatic degradation and immunogenicity, 
avoiding removal by the reticuloendothelial system (RES), as well as increasing 
uptake by cancer cells through high permeability and retention effect (EPR) (Zalipsky 
1995). Doxil is a FDA-approved PEGylated liposomal formulation of the anticancer 
drug doxorubicin which makes use of such properties. Organic micro- and nano-
particles have been investigated in the area of drug delivery. Most of these NPs are 
prepared from non-toxic natural polymers by choice. Besides hydrophilic polymers 
such as PEG, amphiphilic polymers are also useful for synthesizing drug delivery 
vehicles (Torchilin 2007). Polymeric micelles can be made from these polymers for 
encapsulating hydrophobic cancer drugs such as tamoxifen, paclitaxel and 
camptothecin (Chen 2010). When synthetic polymers were used, the inherent toxicity 
was examined at an early stage to avoid problems at the final application stage. 





polymeric micelles are non-toxic or mildly-toxic at high concentrations, unlike NPs 
made from heavy metals. 
Capping agents which bind weakly to the NPs surface can influence the fate of 
NPs in vivo. The blood plasma is a concoction of 3700 identified proteins and they 
compete to bind to the NPs surface (Lynch, Salvati et al. 2009). Proteins with high 
concentrations may first occupy the NPs surface, which are in turn replaced by 
proteins of lower concentrations and higher affinity (Lynch and Dawson 2008). 
Eventually, the cell “sees” and interact with NPs with a constantly changing protein 
corona that is not present on the NPs initially (Klein 2007). The exchange processes 
may also affect NPs redistribution from one compartment or organ to another inside a 
living organism (Lynch and Dawson 2008). 
Often, it is a worry that engineered NPs are discharged or run-off into water 
sources and later be found in our drinking water. Jarvie et al. have shown that the 
stability of NPs in water can be heavily influenced by surface coatings (Jarvie and 
King 2010). Using silica NPs as the model, they showed that NPs coated with the 
surfactant, Tween 20, rapidly aggregated and sedimentated to form solid sewage 
sludge after interacting with organic matter in the sewage wastewater. Owing to the 
presence of many organic compounds, NPs in wastewater can also lose, gain or 
change coatings with time (Jarvie and King 2010). Surprisingly, uncoated NPs which 
were originally stable and dispersed in ultrapure water remained stable in wastewater 
with no sedimentation, and therefore pose a larger threat to our water sources (Jarvie, 






1.5 Platinum nanoparticles (Pt-nps) 
Platinum complexes such as cisplatin have been used for several decades to 
treat a number of conditions. However, the use of Pt-nps as therapeutics is still in its 
infancy. The most common method for the synthesis of Pt-nps is by chemical 
reduction of platinum salts; the most common of additional agents are ethylene glycol 
and sodium borohydride (Eklund and Cliffel 2004; Herricks, Chen et al. 2004). Guo et 
al. synthesized Pt-nps using borohydride as the reducing agent and citric acid as a 
stabilizer (Guo, Zhao et al. 2005). By varying the ratio of citric acid to the platinum 
salt, they synthesized Pt-nps with different sizes. The size and shape of Pt-nps can be 
controlled by the precursor reduction conditions while employing supercritical fluid 
reactive deposition (Gehrke, Pelka et al. 2011). Additionally, Pt-nps exhibit size and 
shape-dependent catalytic properties (Ahmadi, Wang et al. 1996).  
One of the growing areas where potential applications are being explored is 
nanomedicine. Preliminary reports have shown that Pt-nps which formed complexes 
with other metals had remarkable anticancer properties (Gao, Liang et al. 2007). 
Scientists are exploring ways to exploit the potential of Pt-nps and to develop a highly 
specific targeted nano-platinum drug. Pt-nps complexed with CNTs, find other 
applications in medicine as DNA biosensors, owing to their superior catalytic 
properties (Wang, Liu et al. 2006). 
 
1.6 Nanomedicine 
Applications of nanotechnology for treatment, diagnosis, monitoring, and 
control of biological systems are referred to as "nanomedicine" by the National 
Institutes of Health (Moghimi, Hunter et al. 2005). Biomedical nanotechnology is an 





(Arvizo, Bhattacharyya et al. 2012). Important biomedical applications of 
nanotechnology that may have potential clinical applications include targeted drug 
delivery, detection, diagnosis and imaging. Basic understanding of how NMs, the 
building blocks of nanotechnology, interact with cells and their biological 
consequences are beginning to evolve.  
Noble metal NPs such as gold, silver and platinum are particularly interesting 
due to their size and shape dependent unique optoelectronic properties. These noble 
metal NPs have elicited a lot of interest for important biomedical applications because 
of their ease of synthesis, characterization and surface functionalization. Drugs can be 
loaded onto NPs by methods such as encapsulation, surface attachment or entrapment. 
NPs can efficiently penetrate across barriers through small capillaries into individual 
cells, allowing efficient drug accumulation at the target site. Therefore, the unwanted 
side effects and toxicity of the therapeutic agent are greatly reduced (Yih and Al-
Fandi 2006). NPs in the pharmaceutical biotechnology sector serve to improve the 
therapeutic index of drugs and provide solutions to future delivery problems for new 
and upcoming classes of biotechnological products such as recombinant proteins and 
oligonucleotides. New therapeutic opportunities are opened for therapeutic agents that 
cannot be used as conventional drug formulations due to poor bioavailability or drug 
instability. Advantages of nano-formulations include: (i) improving the solubility and 
stability of drugs, (ii) allowing a prolonged release of drugs, (iii) increasing 
bioavailability of drugs, (iv) providing a targeted release platform and (v) using lesser 
drugs and lowering toxicity of the formulation (Parveen, Misra et al. 2012). Because 
of these properties, diverse types of NPs can be used to deliver therapeutics to the site 





modifiers are often added, forming a layer which offers repulsive force between NPs 
and preventing flocculation (Dutta and Green 2008). 
 
1.7 Body portals of nanomaterials 
Since many commercial products contain NMs, exposure of NMs to an 
organism can occur in various ways, with common routes of entry being inhalation, 
ingestion, dermal absorption and through therapeutic applications. A schematic map 






Figure 1.4: Potential routes of exposure, translocation and deposition sites of 
nanomaterials. Bold arrows refer to routes which have been demonstrated and 
reported. It should be noted that translocation, accumulation and retention rates may 
vary with physicochemical properties of the nanomaterials and the experimental 







Systemic availability of NPs after inhalation is driven by factors such as the 
exposure time and concentration, method of NPs administration, NPs size and 
agglomeration state (Johnston, Hutchison et al. 2010). Ultrafine particles (UFPs,        
< 100 nm) were the crucial cause of respiratory disorders and these were more toxic 
and caused greater inflammation in test animals than larger particulates (Zhu, Feng et 
al. 2009). Moreover, the size distribution of the NPs affects the target regions of 
deposition in the respiratory tract, where smaller particles were found to penetrate 
deeper (Oberdorster, Oberdorster et al. 2005). NPs can penetrate the alveoli and get 
absorbed by the lung, or could be cleared by macrophages (Semmler-Behnke, 
Kreyling et al. 2008). This process is influenced by the size and shape of NMs (Elder, 
Yang et al. 2007).  
CNTs were reported to impair phagocytosis, causing the release of 
chemokines and cytokines and impairing their functions (Shvedova, Fabisiak et al. 
2008). On the other hand, smaller particles (less than 70 nm) are less efficiently 
phagocytosed, as macrophages cannot recognize ultra small particles below a 
phagocytic cut off size of 500 nm (Rupper and Cardelli 2001; Champion, Walker et al. 
2008). In some cases, NPs can impair the phagocytic capacity of alveolar 
macrophages, leading to apoptosis (Oh, Kim et al. 2010). Occupational exposure of 
workers to NPs generated pleural granuloma formation characterized by shortness of 
breath and pulmonary fibrosis (Song, Li et al. 2009).  
NPs of size below 400 nm have a high chance of crossing the lung–epithelial 
barrier and enter the blood or lymphatic systems which are subsequently transported 
to different organs. Also, particle-laden macrophages also play a part in distributing 





(Semmler-Behnke, Kreyling et al. 2008) and Ag (Kim, Kim et al. 2009) NPs in 
animal models resulted in systemic distribution and subsequent deposition in various 
organs. Inhalation of Ag NPs was not found to cause any change to the nasal mucosal 
architecture significantly (Hyun, Lee et al. 2008). Nonetheless, inhalation of 
commercially available products such as “Magic Nano” sprays resulted in serious 
lung injury, haemorrhage and subsequent death in rat models (Pauluhn, Hahn et al. 
2008). 
 
1.7.2 Absorption through the skin 
The human skin is an effective barrier against NPs and chemicals. The 
strongly keratinized stratum corneum (10 mm thickness) expels foreign bodies 
effectively. However, sweat glands and hair follicles could make this barrier more 
vulnerable and facilitate entry of NMs. TiO2 NPs is an effective UV filter added to 
sunscreen lotions. Micron and sub-micron sized TiO2 NPs were shown to cross the 
skin and reach hair follicles and dermis after the horny layer had been removed 
(Lademann, Weigmann et al. 1999). TiO2 NPs were not detected in viable non-
damaged skin layers (Mavon, Miquel et al. 2007). However, NPs can reach into the 
viable skin regions in the dermis and epidermis when the skin is wounded or abrased. 
Surface coatings on TiO2 NPs can affect indirect skin damage by controlling the 
reactive surface available for photocatalysis, which generates harmful ROS (Carlotti, 
Ugazio et al. 2009). 
Skin absorption of NMs was proposed to occur through interactions with lipid 
systems of the skin and subsequent phagocytosis by Langerhans cells (Hoet, Brüske-
Hohlfeld et al. 2004). TiO2 NPs are associated with exacerbation of atopic dermatitis 





et al. 2009). The uptake of metallic NPs through the skin has been considered more 
obscure than other routes of entry. Parameters such as clothing, dose, age, type and 
condition of the skin are expected to be involved in this process.  
Ag NPs dissolved in synthetic sweat exhibited low penetration in intact and 
damaged human skin, suggesting their safe application on intact skin (Larese, 
D'Agostin et al. 2009). The damaged skin used in the experiment showed significant 
absorption of Ag NPs when compared to intact skin. Ag NPs are usually applied as 
wound dressings on damaged skin which may facilitate rapid penetrations. Filon et al. 
have studied the effect of cobalt NPs in human volunteers and established their skin 
penetration potentials (Filon, Maina et al. 2004). Skin irritations and ulcerations have 
been reported for ZnO NPs in in vivo models such as the zebrafish (Zhu, Zhu et al. 
2008). Also, similar work on damaged rat skin showed increased penetration of QDs 
(Zhang and Monteiro-Riviere 2008). These reports emphasize that NPs could 
penetrate faster in a damaged skin under normal conditions. Concisely, NPs are 
capable of crossing both intact and damaged skin at different rates, a property which 
is controlled by intrinsic parameters of the material. 
 
1.7.3 Ingestion 
NPs which are employed as food additives and drugs are likely to get absorbed 
into the body through the gastrointestinal tract (GI), which is one of the potential 
routes for the entry of particles. From the GI tract, they can enter lymphatic tissues 
containing phagocytic cells. Multiple parameters such as size, surface charge, 
attachment to ligand or type of ligand could control their targeting and absorption in 
the GI tract (Hillyer and Albrecht 2001). Ingested NMs are likely to get expelled if 





trigger agglomeration of NMs inside the intestinal tract. If agglomerates are small 
enough, they can get expelled through faeces with little absorption. Bigger 
agglomerates can result in obstruction of GI tract and death. This idea was 
experimentally proven in mice fed with zinc NPs. Following exposure to these NPs, 
mice developed severe diarrhoea, vomiting and anorexia followed by death. Autopsy 
revealed clumps of particles blocking the intestine (Wang, Feng et al. 2006). Ingestion 
of polystyrene NPs by rats resulted in absorption through the GI tract (Jani, Halbert et 
al. 1990), whereas fullerenes were cleared within 48 h (Yamago, Tokuyama et al. 
1995). On the other hand, 15 nm Au NPs showed higher penetration rates in rat 
intestinal models as compared to larger size (102 and 198 nm) Au NPs (Sonavane, 
Tomoda et al. 2008). These reports suggest that NPs could penetrate the GI tract, 
resulting in translocation to other organs. 
 
1.7.4 Translocation 
From the site of entry, NPs can enter the circulatory system (Furuyama, Kanno 
et al. 2009; Zhu, Feng et al. 2009). Intra-tracheal instillation of 30 nm Au NPs 
translocated to platelets within 30 min (Berry, Arnoux et al. 1977). Carbon NPs 
showed a rapid diffusion (5 min) from lung to blood in hamster models (Nemmar, 
Vanbilloen et al. 2001) and in human subjects (Oberdorster, Sharp et al. 2004). Many 
animal experiments have shown rapid translocation of NPs from the site of entry to 
target organs such as brain, spleen, liver, kidney and muscles through blood 
(Oberdorster, Sharp et al. 2004). Once in the blood stream, stable NPs can get 
distributed to various organs where they impart specific side effects. Ag NPs were 
observed to penetrate the chorion of zebrafish embryos and are distributed to the brain, 





body axes, twisted notochord, slow blood flow, pericardial oedema, cardiac 
arrhythmia and apoptosis of cells in various body parts (Figure 1.5). Similar 
phenotypic defects were also caused by multi-walled CNTs (MWCNTs) (Asharani, 
Serina et al. 2008). Recent evidences suggest that the NPs can cross the blood–brain 
barrier and affect brain functions (Sarin, Kanevsky et al. 2008). Many research groups 
have studied the effects of NPs on cardiovascular systems. Exposure of NPs in 
experimental animal models resulted in myocardial infarction (Nemmar, Al-Maskari 
et al. 2007). 
 
Figure 1.5: Optical micrographs of zebrafish embryos 24 hours post fertilization (hpf) 
(a, b) and 72 hpf (c, d). Untreated, healthy zebrafish embryo had a clear and 
transparent chorion (a), while Ag NPs (5 µg/ml) treated embryos had brown flakes 





zebrafish larvae had normal development (c) and Ag NPs (100 µg/ml) treated 
embryos showed deformities such as bent notochord, pericardial oedema, enlarged 
yolk and abnormal eye formation (d) (Asharani, Wu et al. 2008). 
 
Recent reports have shown anti-platelet properties by Ag NPs (Shrivastava, 
Bera et al. 2009). Our group has investigated the hemocompatibility of Ag, Au and Pt 
NPs with erythrocytes (Asharani, Sethu et al. 2010). Erythrocytes exhibited 
significant lyses, hemagglutination, membrane damage, detrimental morphological 
variations and cytoskeletal distortions following exposure to Ag NPs at a 
concentration of 100 µg/ml, while Au and Pt NPs remained hemacompatible at the 
same concentration (Figure 1.6).  
 
Figure 1.6: Optical micrographs of normal (a) and Ag NPs treated (b) erythrocytes. 
With Ag NPs (400 µg/ml) treatment, erythrocytes showed haemolyses and appeared 
as ghost cells (circled). SEM images of erythrocytes with normal biconcave structure 
(c), while Ag NPs (400 µg/ml) treatment induced aberrant morphology (d) (Asharani, 






Exposure of 23.5 nm copper NPs in mice via oral gavage damaged the liver, 
spleen and kidneys, while micron-sized particles did not show the same effect (Chen, 
Meng et al. 2006). Exposure to ZnO NPs resulted in necrosis of liver tissues and 
severe renal damage (Wang, Feng et al. 2006). The effects of long term deposition of 
metallic NPs in various organs are still largely unknown. They may lead to organ 
dysfunction at later stages, which can be dependent on various factors such as dose, 
mode of intake, stability and the properties of NPs. 
 
1.7.5 Excretion of nanoparticles 
Even though literature reports may suggest various routes for excretion of NPs, 
only a few have been proven experimentally. NPs are proposed to be expelled through 
urine, faeces, sweat, breast milk and saliva (Oberdorster, Oberdorster et al. 2005). 
However, experimental evidence support excretion only through urine (Burns, Vider 
et al. 2009) and faeces (Cho, Cho et al. 2009). Expulsion of NPs through the kidney 
(i.e. urine) is dependent on various parameters such as size, surface functionality and 
aspect ratio. The size of NPs can affect renal excretion and QDs (< 5.5 nm) were 
rapidly eliminated in the rat model, while renal excretion was prevented when 
proteins adsorbed on the surface of QDs, resulting in the hydrodynamic diameter to 
increase by more than 15 nm (Choi, Liu et al. 2007). Surface functionality also played 
an important role in regulating renal excretion. Souris et al. reported that highly-
charged mesoporous silica NPs (+34.4 mV at pH 7.4) were rapidly excreted in the 
faeces as compared to lesser-charged particles (-17.6 mV at pH 7.4). However, it was 
unclear whether the magnitude of the charge or nature of the charge (+/-) had really 
caused the difference in excretion (Souris, Lee et al. 2010). NMs with high aspect 





et al. 2008). Excretion of these NMs requires individualized, well-dispersed 
MWCNTs to align their longitudinal axis perpendicular to the endothelial 
fenestrations during translocation through the glomerular filtration barrier. This 
indicates that CNT dispersions that were not individualized, or that have aggregated 
in vivo, may be retained by the kidney.  
The kidney therefore becomes one of the target organs for NP toxicity. Mice 
exposed to Cu NPs resulted in glomerulitis, degeneration, necrobiosis, oedema and 
discoloration of kidneys (Chen, Meng et al. 2006). Cu NPs also altered metabolic 
functions in the kidney leading to nephrotoxicity as well as hepatoxicity. These 
evidences suggest that NPs are able to damage the excretory systems, leading to NP 
retention and organ failure. 
 
1.7.6 Biodistribution at the cellular level 
Intracellular targets of NPs are largely unknown and can vary widely 
depending on particle functionalization, while target organs of NPs are well 
documented (Oberdorster, Oberdorster et al. 2005; Asharani, Wu et al. 2008; 
Semmler-Behnke, Kreyling et al. 2008; Johnston, Hutchison et al. 2010). Uptake 
kinetics of Au NPs were reported to occur via receptor mediated clathrin-dependant 
endocytosis (Chithrani, Ghazani et al. 2006; Chithrani and Chan 2007). Chithrani et al. 
have shown that the wrapping of plasma membranes is faster for 50 nm NPs as 
compared to NPs of other sizes, which resulted in their faster uptake. A shape-
dependant study proved that spherical NPs are taken up faster than nanorods 
(Chithrani, Ghazani et al. 2006). However, study on the exocytosis kinetics showed an 
inverse relation, where 14 nm Au NPs were expelled much faster than 74 nm NPs 





route for uptake of different NMs (Au, CNTs and silica) (Xing, He et al. 2005; Jin, 
Heller et al. 2009). However, clathrin-knockdown rabbit conjunctiva cells were also 
able to endocytose chitosan NPs efficiently, suggesting the involvement of other 
pathways in NP uptake process (Huang, Ma et al. 2002). Rejman et al. studied 
fluorescent latex particle uptake and suggested that smaller particles (< 200 nm) are 
internalized by clathrin-mediated endocytosis, whereas, particles larger than 500 nm 
are internalized by caveolae-mediated endocytosis (Rejman, Oberle et al. 2004). It is 
likely that mechanisms other than phagocytosis exist for the uptake of NPs, as most of 
the non-phagocytic cells were also taking up NPs efficiently. Macropinocytosis is also 
documented as one of the mechanisms for the uptake of NPs (Walsh, Tangney et al. 
2006). Macropinosomes are larger structures (1 mm) as compared to clathrin pits (150 
nm), but the selection between the two processes remain obscure (Nichols and 
Lippincott-Schwartz 2001). Due to the limited number of reports on the uptake of NPs, 
it is difficult to conclude at the current state on a common mechanism which regulates 
the uptake for all types of NMs.  
Following uptake, Au NPs have been observed to interact with endosomal 
proteins, escaping from endosomes and cluster in the cytosol and perinuclear regions, 
while some NPs entered the nucleus (Thomas and Klibanov 2003). To enter the 
nucleus, NPs could pass through the nucleus envelope via the channels provided by 
nuclear pore complexes or by attachment with a nuclear localization signal (Misra and 
Sahoo 2010) in the cytosol. Au NPs in the nucleus induced cytokinesis arrest, causing 
binucleated cell formation to occur after mitosis has taken place which finally led to 







1.8 Passive targeting: Enhanced Permeability and Retention (EPR) effect 
Solid tumours have unique pathophysiological characteristics which are not 
observed in normal tissues (Maeda, Wu et al. 2000). These include extensive 
angiogenesis, hypervasculature, defective vascular architecture, impaired lymphatic 
drainage-recovery system, and increased production of permeability mediators. This 
phenomenon is known as the enhanced permeability and retention (EPR) effect and 
has been observed to be universal in tumours. Enhanced vascular permeability helps 
sustain an adequate supply of nutrients and oxygen for rapid tumour growth. In 
addition, the lack of effective lymphatic drainage has allowed targeting using 
macromolecular drugs, lipids, liposomes, etc, which led to accumulation of drug 
delivery vehicles at the tumour. 
The EPR effect has been observed in many experimental and human solid 
tumours, such as S-180 sarcoma, Meth-A, melanoma B16 and Ehrlich carcinoma; 
colon 38 adenocarcinoma in mice; Yoshida AH136B, Walker 256 carcinoma and LY 
tumours in rats; VX-2 carcinoma in rabbits; and many humans tumours, including 
hepatoma, renal cancer, lung cancer and brain tumours (Maeda, Wu et al. 2000). 
Small molecules such as molecular chemotherapeutic drugs are governed by free 
diffusion-dependent equilibrium and therefore do not discriminate tumour tissue from 
normal tissue (Maeda 2001). They do not exhibit the EPR effect. 
 NPs are usually be taken up by the liver, spleen and the RES depending on 
their surface characteristics (Brannon-Peppas and Blanchette 2004). Particles with 
more hydrophobic surfaces will be preferentially taken up by the liver, followed by 
the spleen and lungs (Brigger, Dubernet et al. 2002). Hydrophilic NPs such as those 
prepared from poly(vinyl pyrrolidone), show less than 1% uptake by the spleen and 





(Gaur, Sahoo et al. 2000). NPs with longer circulation times and hence greater ability 
to target to the site of interest, should be smaller than 100 nm in diameter and have a 
hydrophilic surface in order to reduce clearance by macrophages (Storm, Belliot et al. 
1995). Coatings of hydrophilic polymers can create a cloud of chains at the particle 
surface which will repel plasma proteins. 
Systems that have been approved include liposomal doxorubicin (Myocet, 
Elan Pharmaceuticals), PEGylated liposomal doxorubicin (Doxil, Ortho Biotech and 
Caelyx, Schering Plough), PEGylated liposomal daunorubicin (DaunoXome, Diatos), 
and the recently approved albumin-bound paclitaxel-loaded NPs (Abraxane, Abraxis 
Bioscience) (Byrne, Betancourt et al. 2008). 
 
1.9 Active targeting: Using biological molecules 
Active targeting requires the conjugation of receptor-specific ligands that can 
promote site-specific targeting (Molema, Meijer et al. 1998; Thorpe 2004). The 
success of drug targeting depends on the selection of an appropriate targeting moiety. 
It should be highly abundant, having high affinity and specificity of binding to cell 
surface receptors and should be able to withstand chemical modification by 
conjugation. Active targeting can be achieved by molecular recognition of the 
diseased cells by the signature molecules over-expressed on their surface. The 
therapeutic agent can be actively targeted by conjugating the carrier with a cell- or 
tissue-specific ligand, thereby allowing a preferential accumulation of the drug at the 
diseased site. Using active targeting, efficient cellular uptake and intracellular 
internalization can be achieved. PEGylated Au NPs are decorated with various 
amounts of human transferrin to enhance active targeting (Choi, Alabi et al. 2010). 





therapeutic agents to cancer cells than the non-targeted analogues. In another study, 
cancer cells were actively targeted using PLGA NPs that were surface-modified with 
monoclonal antibody (Kocbek, Obermajer et al. 2007). This demonstrated the 
superior capability of active recognition of the surface-modified NPs as they showed 
enhanced binding to the targeted cells than non-coated NPs. Examples of suitable 
ligands include proteins (antibodies and their fragments), nucleic acids (aptamers) and 
receptor ligands (peptides, vitamins, and carbohydrates) (Peer, Karp et al. 2007; 
Byrne, Betancourt et al. 2008). 
 
Figure 1.7: Schematic representation of different mechanisms by which nanocarriers 
can deliver drugs to tumours. Passive tissue targeting is achieved by extravasation of 
NPs through increased permeability of the tumour vasculature and ineffective 
lymphatic drainage (EPR effect). Active cellular targeting (inset) can be achieved by 
functionalizing the surface of NPs with ligands that promote cell-specific recognition 
and binding. NPs can (i) release their contents in close proximity to the target cells; (ii) 
attach to the membrane of the cell and act as an extracellular sustained-release drug 







1.10 Rationale of this study 
The types of NPs currently used in research for cancer therapeutic applications 
include dendrimers, liposomes, polymeric micelles, protein NPs, ceramic NPs, viral 
NPs, metallic NPs and CNTs. Given the diverse variety of drug delivery vehicles to 
choose from, it is important to select one which is easy to synthesize, characterize, 
purify, non-toxic and could even exhibit therapeutic effects on its own. A careful 
survey of this long list of NMs revealed platinum nanoparticles (Pt-nps) as a potential 
candidate which fulfils all requirements. Although platinum (metal, salts and particles) 
is known for its catalytic properties in chemical reactions, little is known about its 
medical and biological properties. As mentioned earlier, few reports have indicated 
that Pt-nps can be easily synthesized via the bottom-up approach from its salts, 
relatively non-toxic, hemacompatible and may have anticancer properties. 
Functionalization of NPs is necessary to create a stealth surface from 
opsonisation, the adherence of serum proteins to the NPs surface. This increases 
circulation time through avoidance of removal by the RES. Incorporation of a 
hydrophilic polymer, such PEG or PVP, to the surface of the NPs greatly improves 
solubility and a reduction in opsonisation. With increased circulation time, the tumour 
can have higher NPs uptake via passive targeting or EPR effect. For such reasons, 
PVP being biocompatible and water-soluble is employed. 
To further improve site-specific targeting effects and reducing toxicity, active 
targeting can be used in conjunction with passive targeting. A careful analysis of 
available in vitro and in vivo models revealed folic acid and galactose as suitable 
receptor-specific ligands. Folic acid targets cancer cells which over-expressed folate 





asialoglycoprotein receptors. Folic acid and galactose were adsorbed onto Pt-nps to 
target the appropriate test model in our study.  
5-Fluorouracil is chosen as the chemotherapeutic drug to be carried by Pt-nps. 
Its principal uses are in colorectal cancer, pancreatic cancer, breast cancer, head and 
neck cancer, liver cancer and ovarian cancer in the form of chemotherapy 
(intravenous injection). Cancerous tumours are characterized by uncontrolled cell 
division. Chemotherapy kills cancer cells by stopping cell division. 5-Fluoruracil is a 
pyrimidine analogue which works through irreversible inhibition of thymidylate 
synthase. In addition, 5-fluorouracil’s anticancer activity was also tested separately in 
our test models so as to enable a comparison between Pt-nps and a commercially 
available drug. 
Herein, we propose a systematic approach to analyse the feasibility of using 
Pt-nps as a drug delivery vehicle and to develop it into a nanomedicine: 
1. Synthesis and purification methods of Pt-nps functionalized with a single 
capping agent or a combination of capping agents (PVP, folic acid, 
galactose and 5-fluorouracil), followed by experimental setups (Chapter 2); 
2. Characterization and in vitro testing of Pt-nps in cancer and normal cell 
lines, in terms of uptake, viability and mechanism of cell death; 
3. In vivo monitoring of zebrafish larvae liver size after exposure to Pt-nps. 
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2. Materials and Methods 
2.1 Preparation for synthesis 
All experiments were performed in a clean environment to eliminate the 
chances of endotoxin contamination that may interfere with the toxicity profile of the 
nanoparticles. Glassware used for synthesis were treated with piranha solution (3 : 1, 
concentrated sulphuric acid : 30% hydrogen peroxide) to remove contaminants prior 
to reaction, if necessary. Starting materials and purchased chemicals were used 
without further purification. 
 
2.1.1 Synthesis of platinum nanoparticles functionalized with poly(vinyl 
pyrrolidone) (Pt-PVP) 
PVP-capped platinum nanoparticles were synthesized via the reduction of 
H2PtCl6.6H2O (Sigma-Aldrich) as reported by van Rheenen et al. with some 
modifications (van Rheenen, McKelvy et al. 1987). H2PtCl6.6H2O (1 g) was dissolved 
in ultrapure water (19 ml, Millipore) to give a stock solution (100 mM). The stock 
solution (500 µl) was subsequently reduced under constant stirring using NaBH4 (10 
mg, Sigma-Aldrich) dissolved in ultrapure water (1 ml). Colloidal solution was then 
stabilized by the immediate addition of PVP (100 mg, Sigma-Aldrich) in ultrapure 
water (10 ml). Final volume of the reaction mixture was kept at 50 ml. The colour of 
the solution changed from yellow to dark brown during the reduction process, 
indicating nanoparticle formation. Stirring was continued for 3 days at room 
temperature. 
A common purification method was used for all nanoparticles. The solution 
was centrifuged at 20000 rpm (JA-20, Beckman) for 45 min to obtain a pellet. The 
pellet was washed twice using ultrapure water (10 ml) to remove traces of unbound 
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capping agent and reducing agent. The purified solution was filtered using a 0.2 mm 
syringe filter to get rid of large particle aggregates. A known amount of dry solid 
obtained after freeze-drying was again resuspended in ultrapure water to get a stock 
solution (1 mg/ml) and subsequently stored at 4 °C. 
 
2.1.2 Synthesis of platinum nanoparticles functionalized with folic acid (Pt-FA) 
H2PtCl6.6H2O (500 µl, 100 mM) stock solution was stirred with folic acid 
dihydrate (200 mg, Alfa Aesar) solution for 5 min. This was subsequently reduced by 
adding a solution of NaBH4 (2.5 mg) in a drop-wise manner. The final volume of the 
reaction mixture was kept at 50 ml and the final pH was adjusted to 7 and stirring was 
continued for 3 days.  
 Pt-FA was purified using a common purification method as mentioned in 2.1.1. 
 
2.1.3 Synthesis of platinum nanoparticles functionalized with folic acid, 5-
fluorouracil and PVP (Pt-FA/5FU/PVP) 
H2PtCl6.6H2O stock solution (500 µl, 100 mM) was introduced into 48.5 ml 
ultrapure water, already pre-dissolved with folic acid (20 mg), 5-fluorouracil (100 mg, 
Sigma-Aldrich) and PVP (5 mg) under constant stirring at 700 rpm. After 15 min, this 
mixture was reduced using NaBH4 (15 mg) dissolved in ultrapure water (1 ml). Final 
volume of the reaction mixture was kept at 50 ml. The final pH was adjusted to 7 and 
stirring was continued for 3 days. 
Pt-FA/5FU/PVP was purified using a common purification method as 
mentioned in 2.1.1. 
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2.1.4 Synthesis of platinum nanoparticles functionalized with galactose, 5-
fluorouracil and PVP (Pt-Gal/5FU/PVP) 
H2PtCl6.6H2O stock solution (500 µl, 100 mM) was introduced into 48.5 ml 
ultrapure water, already pre-dissolved with D-galactose (20 mg, Duchefa Biochemie 
B. V.), 5-fluorouracil (100 mg) and PVP (5 mg) under constant stirring at 700 rpm. 
After 15 min, this mixture was reduced using NaBH4 (15 mg) dissolved in ultrapure 
water (1 ml). Final volume of the reaction mixture was kept at 50 ml. The final pH 
was adjusted to 7 and stirring was continued for 3 days. 
Pt-Gal/5FU/PVP was purified using a common purification method as 
mentioned in 2.1.1. 
 
2.1.5 Synthesis of platinum nanoparticles functionalized with 5-fluorouracil and 
PVP (Pt-5FU/PVP) 
H2PtCl6.6H2O stock solution (500 µl, 100 mM) was introduced into 48.5 ml 
ultrapure water, already pre-dissolved with 5-fluorouracil (100 mg) and PVP (5 mg) 
under constant stirring at 700 rpm. After 15 min, this mixture was reduced using 
NaBH4 (15 mg) dissolved in ultrapure water (1 ml). Final volume of the reaction 
mixture was kept at 50 ml. The final pH was adjusted to 7 and stirring was continued 
for 3 days. 
Pt-5FU/PVP was purified using a common purification method as mentioned 
in 2.1.1. 
 
2.1.6 Synthesis of platinum nanoparticles functionalized with galactose and 5-
fluorouracil (Pt-Gal/5FU) 
H2PtCl6.6H2O stock solution (500 µl, 100 mM) was introduced into 48.5 ml  
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ultrapure water, already pre-dissolved with D-galactose (20 mg) and 5-fluorouracil 
(100 mg) under constant stirring at 700 rpm. After 15 min, this mixture was reduced 
using NaBH4 (15 mg) dissolved in ultrapure water (1 ml). Final volume of the 
reaction mixture was kept at 50 ml. The final pH was adjusted to 7 and stirring was 
continued for 3 days. 
 Pt-Gal/5FU was purified using a common purification method as mentioned in 
2.1.1. 
 
2.1.7 Synthesis of platinum nanoparticles functionalized with galactose and PVP 
(Pt-Gal/PVP) 
H2PtCl6.6H2O stock solution (500 µl, 100 mM) was introduced into 48.5 ml 
ultrapure water, already pre-dissolved with D-galactose (20 mg) and PVP (5 mg) 
under constant stirring at 700 rpm. After 15 min, this mixture was reduced using 
NaBH4 (15 mg) dissolved in ultrapure water (1 ml). Final volume of the reaction 
mixture was kept at 50 ml. The final pH was adjusted to 7 and stirring was continued 
for 3 days. 
Pt-Gal/PVP was purified using a common purification method as mentioned in 
2.1.1. 
 
2.1.8 Synthesis of platinum nanoparticles functionalized with galactose and 
cysteamine-AF594 (Alexa Fluor 594, fluorescent dye) conjugate (Pt-Gal/Dye) 
 The synthesis of a fluorescent Pt-np involves 3 steps: (a) synthesis of platinum 
nanoparticles capped with galactose (Pt-Gal); (b) synthesis of cysteamine-dye 
conjugate and (c) ligand exchange of cysteamine-dye conjugate with Pt-Gal. 
 Pt-Gal was synthesized by adding H2PtCl6.6H2O stock solution (500 µl) into  
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49.5 ml ultrapure water, already pre-dissolved with D-galactose (200 mg) under 





. The resulting brown solid was resuspended in water, sonicated and filtered 
using a 0.2 mm syringe filter to get rid of large particle aggregates. The colloid was 
dialyzed using a semi-permeable membrane (MWCO 3200, Thermo Scientific) 
against ultrapure water to remove excess H2PtCl6 and galactose. A Benedict’s test was 
carried out to confirm the presence of galactose on Pt-Gal. 
 Cysteamine acts as the linker to between platinum and the fluorescent dye. To 
synthesize the cysteamine-dye conjugate, cysteamine (12.5 mg, Sigma-Aldrich) was 
first dissolved in PBS (10 ml) to form a stock solution. The stock solution (0.1 ml) 
was diluted using PBS (4.9 ml) to get a 10 mM solution. Alexa Fluor 594 C5 
maleimide (1 mg, Life Technologies) was dissolved in DMSO (100 µl, Sigma-Aldrich) 
to form a 11 mM solution. The dye was added dropwise to a stirring solution of 
cysteamine at room temperature (25 
o
C), under N2 atmosphere and protected from 
light. Stirring continued for 2 h in order for the nucleophilic reaction to complete. 
 To carry out ligand exchange, the cysteamine-dye conjugate (500 µl) was 
added to Pt-Gal (1 ml) and diluted with PBS (3.5 ml) to make up a final volume of 5 
ml. The mixture was stirred for 2 days at room temperature. The colloid was dialyzed 
using a semi-permeable membrane against ultrapure water to remove excess reagents.  
 
2.2 Characterization 
2.2.1 UV-visible (UV-vis) spectroscopy 
UV-visible measurement of stock solutions of Pt-nps and their capping agents 
were performed using a spectrophotometer (Shimadzu UV-1601PC) at room 
temperature. 
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2.2.2 Elemental analysis 
Freeze-dried NPs were analyzed for their respective elemental composition. 
Carbon, hydrogen and nitrogen analysis were performed using Elementar Vario 
Microcube. Inductively-coupled plasma (ICP) analysis was used for the determination 
of platinum and silver levels in acid digested nanoparticles solutions. Sample 
preparation was done with a Milestone microwave laboratory system, while ICP was 
performed using Dual-view Optima 5300 DV ICPOES. A modular ion 
chromatography system was used for the determination of anions such as F
-
 with 
chemical suppression. Instrumentation includes Metrohm 818 IC Pump, 820 IC 
Separation Center, 830 Interface, 833 IC Liquid handling Unit, 732 IC Detector and 
813 Compact Autosampler. 
 
2.2.3 Transmission electron microscopy (TEM) 
NPs were observed using JEOL 2010-F Field Emission Transmission Electron 
Microscope (FETEM) and JEOL 3010 High Resolution Transmission Electron 
Microscope (HRTEM). For sample preparation, a dilute solution of NPs dispersed in 
ultrapure water was placed onto a carbon-coated copper grid (400 mesh) supported on 
a clean filter paper and left to dry in an oven overnight. This was subsequently used 
for TEM.  
 
2.2.4 Dynamic light scattering (DLS) and zeta potential measurements 
To find out the hydrodynamic size and surface charge of NPs, dynamic light 
scattering (DLS) and zeta potential measurements were performed using Malvern 
Zetasizer Nano-ZS. Stock solutions were held in appropriate cuvettes or solution 
holders, measured at room temperature and diluted when necessary. 
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2.3 In vitro studies 
2.3.1 Cell culture 
Normal human lung fibroblast, IMR90, (Coriell Cell Repositories, USA, 
passage 18 ± 3) were cultured in minimum essential medium with glutamine (MEM, 
PAA Laboratories) supplemented with 15% foetal bovine serum (FBS, Standard 
Quality, EU-approved origin, PAA Laboratories), 1% each of penicillin, streptomycin, 
non-essential amino acids, vitamins and 2% essential amino acids (Gibco, Invitrogen). 
Human cervical cancer, HeLa; human hepatocellular carcinoma cells, HepG2, and 
human breast cancer cells, MCF7 were purchased from American Type Culture 
Collection (ATCC, USA). Cancer cell lines were maintained in Dulbecco’s Modified 
Eagles Medium (DMEM) supplemented with 10% FBS and 1% penicillin–
streptomycin. Cells were sub-cultured at 80 – 90% confluence and maintained at 
37 °C in a humidified incubator supplied with 5% CO2. IMR90 served as a 
representation of normal cell lines, while various cancer cell lines were studied 
because of different surface receptors. 
 
2.3.2 Brightfield and darkfield (CytoViva) microscopy 
To visualise cell lines under a microscope, the cell type of interest was 
cultured in a 24 - well plate (Griener Bio-one GmbH) where one sterilized VFM 
coverslip (CellPath) was laid at the bottom of the well. The coverslip was washed and 
soaked in sterile PBS for 10 min to condition before the addition of 10000 cells in 
media (1 ml), respectively, into each well. Spent media was aspirated the next day and 
replaced with fresh media. Coverslips were removed from the wells and rinsed with 
fresh media before placing facedown onto a clean glass slide for observation. 
Brightfield images of cell lines were captured using Olympus BX61 microscope with 
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cell^P imaging software (v3.0). Darkfield images were captured using Nikon E200 
microscope with CytoViva ultra-high resolution illumination systems as the light 
source. 
 
2.3.3 Cell viability assay (CellTiter-Glo) 
The viability of Pt-nps treated cells was measured using CellTiter-Glo 
luminescent cell viability assay (Promega) following the manufacturer’s instructions. 
This assay is a homogeneous method for determining the number of viable, 
metabolically-active cells in a culture based on the quantification of ATP 
concentration. The reagent contains detergents to break the cell membrane, causing 
ATP release into the medium and ATPase inhibitors to stabilize the released ATP. 
The addition of an equal volume of reagent to the cell medium generates a 
luminescent signal proportional to the concentration of ATP present in cells. The 
assay is based on the conversion of luciferin to oxyluciferin by a recombinant 
luciferase in the presence of ATP. The observed luminescence is proportional to the 
quantity of ATP where viable cells produce more ATP than non-viable cells. The 
experiments were performed in white, opaque-walled 96 - well plates (Corning, 
Costar). Additional controls were included in this test to rule out autoluminescence or 
quenching by Pt-nps. For the ATP assay, 5000 cells were plated per well and 
incubated in media (100 µl) overnight for cells to adhere to the bottom of the well. 
Spent media was aspirated the next day and replaced with fresh media and cells were 
treated with different concentrations of NPs (25, 50, 100, 200, and 400 µg/ml) for 24, 
48 and 72 h for all cell types. At respective time points, CellTiter-Glo viability assay 
(100 µl) pre-warmed to room temperature was added into each well and mixed 
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properly. After 15 min, luminescence values were measured using Tecan Infinite 
F200 micro-plate reader. 
 
2.3.4 Apoptosis assay 
Annexin-V staining was performed to differentiate apoptosis from necrotic 
cell death induced by Pt-nps. Annexin-V has a high affinity for phosphatidylserine, 
which is translocated from the inner to the outer leaflet of the plasma membrane at 
early stages of apoptosis. Its conjugation with the fluorescent probe FITC facilitates 
measurement by cytometric analysis. Propidium iodide (PI) staining helps to 
distinguish between apoptosis and necrosis due to differences in permeability of PI 
through the cell membranes of live and damaged cells. Pt-nps treated cells were 
harvested and washed twice in DPBS (Sigma-Aldrich) and stained (Annexin-V FITC 
apoptosis detection kit, Sigma-Aldrich) as per manufacturer’s instructions. Flow 
cytometry was performed using Epics Altra (Beckman and Coulter) at an excitation 
wavelength of 490 nm and emission wavelength of 610 nm. Data was collected for 
10000 gated events and analyzed using Summit V4.3.02 software. 
 
2.3.5 Drug (5FU) release kinetics of Pt-FA/5FU/PVP and Pt-Gal/5FU/PVP 
Freeze-dried Pt-nps were used for preparation of stock solutions (1 mg/ml). 
Data were obtained from triplicates using the dialysis bag method following reported 
procedures (Cheng, Peng et al. 2009; Wilson, Samanta et al. 2010). 5FU release study 
was carried out in the dialysis membrane tubing (MWCO 3200, Thermo Scientific). 
Pt-nps cannot cross the membrane, while 5FU can easily diffuse out. Once the 
lyophilized Pt-nps were dispersed in water, they were immediately transferred into the 
dialysis membrane tubing. Typically, Pt-nps solution (1 ml) in dialysis membrane 
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tubing was incubated at 37 ± 0.5 °C in phosphate buffer saline (PBS, 20 ml). An 
aliquot (0.6 ml) was taken at pre-determined time intervals over the period of 24 h. 
The total volume of PBS was maintained by adding the same volume of fresh PBS 
after every aliquot removal. The cumulative release profile of 5FU from the Pt-nps 
was obtained via concentration correction (the amount of 5FU in each aliquot was 
calculated to correct the overall cumulative releasing of 5FU) of released 5FU based 
on the following equation: C′t = Ct + (ν/V)Σ0
t-1
Ct, where C′t is the corrected 
concentration at time t, Ct is the apparent concentration at time t, ν is the volume of 
the aliquots taken, and V is the total volume of buffer. 
 
2.4 In vivo studies 
2.4.1 Collection of zebrafish (Danio rerio) embryos 
Zebrafish embryos were collected from the zebrafish aquarium in the 
Department of Biological Sciences, National University of Singapore and staged 
according to standard procedures (Westerfield 2000). For this study, 20 healthy 
embryos were placed in each well of a 24 - well plate along with embryo water (1 ml); 
or a 6 – well plate along with embryo water (6 ml). Healthy, fertilized embryos were 
selected at early stages (4 – 16 cell stage) with the aid of an optical microscope. 
Fertilized embryos are indicated by dividing blastomeres and transparency, while 
embryos with abnormalities such as asymmetry and presence of vesicles in the yolk 





Materials and Methods 
41 
 
2.4.2 Active Pt-nps delivery into transgenic zebrafish (Tet-on EGFP-kras
v12
) liver 
(fluorescence microscopy)  
Heterozygous transgenic embryos at 48 hours post fertilization (hpf) were 
treated with doxycycline (10 µg/ml, Sigma-Aldrich) for 48 h. Transgenic larvae 
which express oncogenic Kras in the liver after induction by doxycycline were 
identified by their GFP expression and randomized into a 6 - well plate (Griener Bio-
one GmbH) with 20 larvae in each well. Doxycycline controls were given 
doxycycline (10 µg/ml) while the Pt-nps treatment groups were given either 25 µg/ml 
or 50 µg/ml nanoparticles solution, also with doxycycline (10 µg/ml). Preliminary 
experiments have shown that Pt-nps concentrations above 50 µg/ml could cause 
defects in larvae development and therefore concentrations were kept below this limit. 
LiPan transgenic zebrafish larvae displayed strong expression of Ds-Red RFP (red 
fluorescent protein) in the liver and were included to give an indication of the size of a 
“normal” liver at respective time points (Korzh, Pan et al. 2008). At 6 and 8 dpf 
which corresponds to 2 and 4 days post treatment (dpt), larvae from each group were 
imaged with Zeiss Axiovert 200 M inverted microscope equipped with AxioCam HR 
digital camera. Liver size was calculated using Adobe Photoshop (v7.0). 
 
2.4.3 PCNA staining of transgenic zebrafish (Tet-on EGFP-kras
v12
) larvae liver 
Larvae (8 dpf) were fixed with 30% sucrose/2% Bactoagar at room 
temperature. The embryos were cryo-sectioned at a thickness of 8 µm. Sections were 
fixed with 4% PFA/PBS, washed 3 x 5 min, blocked using 5% BSA with 1% H2O2 
and washed using PBST 3 x 5 min. Slides were incubated in primary antibody (1 : 
1000) overnight at 4 °C followed by secondary antibody (Dako Kit) conjugated with 
HRP for 1 h at room temperature. Slides were rinsed with PBST 3 x 10 min and 
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immersed in DAB colour development solution (1 : 100) for a few minutes, stained 
with Hoechst and finally mounted in Flurosave medium (Calbiochem). Brightfield 
images were taken using Olympus BX61 microscope with cell^P imaging software 
(v3.0). 
 
2.4.4 TEM of zebrafish (Tet-on EGFP-kras
v12
 and wild-type) larvae liver 
Larvae were pre-fixed with 2.5% glutaldehyde and 2% PFA and post-fixed 
with OsO4. After a graded dehydration in 30%, 50%, 70%, 80%, 90%, 95% and 100% 
alcohol, larvae were treated in ethanol/propylene oxide mixture (1 : 1); 100% 
propylene oxide; propylene oxide/resin mixture (1 : 1) and finally embedded in 100% 
resin at 80 °C. Ultramicrotomy was performed using Leica Ultracut UCT with a 
diamond knife to obtain samples with 90 nm thickness. Samples were supported on 
150 mesh copper grid, stained with uranyl acetate and lead citrate and observed using 
JEOL 2010-F FETEM. 
 
2.5 Statistical analysis 
Statistical analyses of the values for all experiments were expressed as mean ± 
standard deviation of at least 3 independent experiments. The data were analyzed 
using Student’s t test where statistical significance was calculated for NPs treatment 
group against untreated (negative control) group. The data were subjected to unpaired 
one-tailed test and those with P < 0.05 were considered as significant.
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In drug development, physicochemical properties such as solubility (Rytting, 
Lentz et al. 2005), bioavailability (Veber, Johnson et al. 2002) and drug targeting 
(Low 2007) are problems commonly encountered by medicinal chemists. With the 
development of nanomaterials, potential solutions for these issues are beginning to 
emerge. During drug development, especially for oral drugs, solubility is often the 
most difficult hurdle to overcome. Various drug-like compounds originate from 
natural sources such as plants and these are often huge organic molecules with low 
solubility in water and body fluids. A common approach to improve solubility and 
absorption by the body is to dissolve the compound in an organic solvent. Cremophor 
EL is one surfactant used to stabilize a non-polar cancer drug such as paclitaxel 
(Gelderblom, Verweij et al. 2001). As Cremophor EL is a huge organic molecule, it is 
not inert to the patient, but also exerts a range of biological side reactions. These 
symptoms include hypersensitivity, hyperlipidemia, abnormal lipoprotein patterns and 
aggregation of erythrocytes, adding to the side effects of the cancer drugs 
(Gelderblom, Verweij et al. 2001). Due to this reason, a biocompatible solvent or 
carrier which can improve drug solubility must be used.  
The ultra-small size of nanoparticles (NPs) offers unique physicochemical 
properties such as a large surface area to mass ratio as well as high reactivity 
(Murakami and Tsuchida 2008; Zhang, Gu et al. 2008). Depending on the nature or 
materials used to synthesize NPs, the solubility of NPs in water differs greatly. A 
simple but effective approach to enhance solubility is to introduce biocompatible 
molecules, for example poly(N-vinyl-2-pyrrolidone) (PVP), as capping agents on the 
surface of nanoparticles (Chen, Falkner et al. 2005).  
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Bioavailability of drugs in the blood can be affected by interactions with other 
drug proteins, metabolism and elimination. A common way to improve drug levels is 
by introducing poly(ethylene glycol) (PEG) on the surface of NPs, which reduces 
protein-binding. By evading RES uptake, NPs have longer circulation half-life and 
better passive targeting outcomes for tumours can be achieved (Gaur, Sahoo et al. 
2000; Li and Huang 2007).  
Although passive targeting increases drug concentrations in tumour 
vasculature in comparison to normal tissues, this is still a non-selective process and 
normal tissues are also able to take up the drug, resulting in undesirable side effects. 
This however, can be improved by introducing targeting moieties such as antibodies 
on NPs which act as the carrier for the drug. Folic acid incorporated NPs are one such 
example which have been found to target cancerous cells which over-express folate 
receptors on their surface (Pan and Feng 2008; Yang, Chen et al. 2008). Taking into 
account solubility, passive and active targeting during the design of NPs, 
nanoparticulate drugs will be able to reach their targets more efficiently at a lower 
concentration. The end-result is faster drug onset and lesser side effects, both 
beneficial to the patient.  
Currently, there are many reports on utilizing folic acid on nanocarriers for the 
active targeting of cancer cells over-expressing folate receptors, but information on 
the linking of folic acid to platinum nanoparticles (Pt-nps) by in situ reduction of 
hexachloroplatinic acid and investigation of toxicity have not yet been reported. We 
therefore demonstrate a simple method for the preparation of folic acid-capped Pt-nps 
(Pt-FA) which showed increased uptake and toxicity in cancer cells over PVP-capped 
Pt-nps (Pt-PVP). Next, we synthesized Pt-nps functionalized with folic acid, 5-
fluorouracil and PVP (Pt-FA/5FU/PVP); and Pt-nps functionalized with galactose, 5-
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fluorouracil and PVP (Pt-Gal/5FU/PVP), to demonstrate that adding important 
biomolecules could improve the viability of normal cells, while retaining the same 
level of toxicity toward cancer cells. The use of Pt-nps as a drug carrier was studied 
by introducing 5-fluorouracil via surface adsorption during synthesis. The rate of 
surface desorption of 5-fluorouracil can be studied. A simple one-pot reaction was 
used to prepare Pt-nps because lesser synthetic steps are required, which ensures high 
reproducibility and yield. Preparation of Pt-nps also involved proper purification and 
characterization, as factors such as purity, size, shape, surface functionalization and 
charge are known to affect a nanomaterial’s toxicity (Teow, Asharani et al. 2011). 
Here, we investigated the in vitro effects of Pt-nps in cell lines (normal human 
fibroblasts, IMR90; human cervical cancer, HeLa; human breast cancer, MCF7 and 
human hepatocellular carcinoma, HepG2) using the following experimental methods 
which were described in detail in Chapter 2 (Materials and Methods): 
1. Synthesis, purification and characterization of Pt-nps (pages 30 – 36); 
2. Darkfield microscopy (CytoViva) – Pt-nps uptake, cell shape, cell viability 
(page 37); 
3. ATP assay (CellTiter-Glo) – cell proliferation (page 38); 
4. Apoptosis assay – mechanism of cell death (pages 39); 








It is important for Pt-nps to maintain their stability in water, buffer and cell 
culture medium as aggregation or agglomeration can reduce their effective 
concentrations in solution. As such, we used water soluble capping agents (Figure 
3.1(a-d)) for the synthesis of Pt-nps. As seen in Figure 3.1(e), the resulting purified 
Pt-nps solutions showed no signs of precipitation and remained stable throughout the 
duration of this study. 
 
Figure 3.1: Water soluble capping agents, including PVP (a), folic acid (b), 5-
fluorouracil (c) and D-galactose (d) were used for the synthesis of Pt-nps, resulting in 
the formation of stable colloids in solution (e). 
 
Pt-PVP acted as the model nanoparticle in our study, as it is the simplest 
water-soluble and stable Pt-nps that can be synthesized. Pt-FA, on the other hand, was 
synthesized to prove that Pt-nps can be actively targeted toward cancer cell lines with 
the aid of a suitable targeting ligand, in this case, folic acid. Pt-FA/5FU/PVP and Pt-
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Gal/5FU/PVP were synthesized as an attempt to improve the targeting effects and 
efficacy of Pt-nps and shall be discussed in the final section of this chapter. 
For the synthesis of Pt-FA, hexachloroplatinic acid and folic acid were mixed 
and stirred before adding sodium borohydride. As for Pt-PVP, the capping agent PVP 
was added immediately after the introduction of sodium borohydride. A colour 
change from yellow to light brown indicated the formation of Pt-PVP. The 
nanoparticles synthesized via the former approach were too small and could not be 
purified using centrifugation. Alternatively, switching the sequence of reagent 
addition produced a pellet after centrifugation which can be easily resuspended in 
water. Uncapped Pt-nps are insoluble in water and appeared as a black suspension 
after rigorous sonication. Such solutions are not stable for long periods and are 
unsuitable for biological studies.  
TEM images revealed that Pt-nps form homogeneous colloids in water with no 
signs of agglomeration (Figure 3.2(a, b)). This is important to make sure that 
individual nanoparticles can be transported across cell membranes. The core size of 
Pt-PVP is in the range of 2–6 nm, while Pt-FA is larger with majority of particles in 
the range of 10–15 nm. Pt-PVP and Pt-FA are water dispersible owing to the 
hydrophilic capping agents which can prevent individual particles from aggregating. 
It should be noted that folic acid is more soluble in buffer solutions than in ultrapure 
water, which is preferred for cell viability assays. DLS measurements have showed 
that the mean hydrodynamic diameters were 13.5 nm and 91.3 nm for Pt-PVP and Pt-
FA, respectively (Figure 3.2(c, d)). PVP confers steric stabilization whereas folic 
acid gives an electrostatic stabilization. In contrast to Pt-PVP, Pt-FA has a highly-
charged surface which is solvated by water molecules, which explains its increase in 
hydrodynamic size after dissolving in water. TEM is used to determine inner core 
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diameter, while the hydrodynamic size distribution includes the solid particle, its 
organic layers (capping agents) and the hydration shell, which explains why DLS 
values are always larger (Barth, Sharma et al. 2010; Kittler, Greulich et al. 2010).  
The zeta potential of Pt-PVP was at -8.0 mV while that of Pt-FA was at -40.5 
mV (Figure 3.2(e, f)). The highly-charged surface of Pt-FA arising from the 
ionization of acid functional groups resulted in a highly negative potential. 
Conversely, PVP is a neutral and hydrophilic polymer which stabilizes Pt-PVP 
through hydrophilic interactions with the solvent and therefore has a low surface 
potential. From Figure 3.2(g), it is apparent that the ratio of capping agent to 
platinum in Pt-PVP is high (high carbon to platinum ratio). On the contrary, low 
carbon content was observed for Pt-FA nanoparticles. Platinum content (12.5% vs. 
18.2%) of both samples were comparable which enables a fair comparison between 
these two nanoparticles in cell viability testing. Oxygen content (estimated) of Pt-FA 
was found to be higher than expected due to its hygroscopic nature. 
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Figure 3.2: Characterization of Pt-nps. TEM images of Pt-PVP (a) and Pt-FA (b). 
Insets represent size distribution of the nanoparticles. Data for the histogram were 
collected from 100 randomly picked particles. Dynamic light scattering histogram of 
Pt-PVP (c) and Pt-FA (d). Zeta potential distribution of Pt-PVP (e) and Pt-FA (f). 
Chemical composition (in wt%) of Pt-PVP and Pt-FA (g). 
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3.2.1 Darkfield microscopy (CytoViva) – Pt-nps uptake, cell shape, cell viability 
Cell lines were grown on coverslips and treated with Pt-nps for 48 h before 
observation using CytoViva. Although the plasma membrane is vaguely observed in 
dark field microscopy, nuclear envelopes, cellular contents and organelles are distinct 
and brightly-illuminated. In the three cell types studied, untreated cells displayed a 
small number of bright, round circles which are evenly distributed throughout the 
cells (Figure 3.3(a, d, g)). The identity of these bright specks (yellow arrows) could 
be organelles or transport vesicles (endosomes) which contain high concentrations of 
ions and proteins. Such bright spots should not be mistaken for Pt-nps aggregates 
(green arrows) which are non-circular (randomly-shaped). Pt-nps are too small to be 
observed directly under a light microscope and therefore the bright objects seen in 
these images are scattered light from Pt-nps.  
Pt-nps were able to enter the cytoplasm but not found inside the nucleus, 
which is consistent with literature findings (Komatsu, Tabata et al. 2008). With Pt-
PVP treatment, cells appear to maintain their structural integrity as the membranes 
remained intact. In contrast, Pt-FA was found to enter cells more efficiently as 
indicated by more white specks. The plasma membranes became less distinct, 
especially in cancer cells. Figure 3.3(c, f) show cell debris resulting from cell death. 
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Figure 3.3: Darkfield optical images of untreated (a), Pt-PVP treated (b) and Pt-FA 
treated (c) HeLa cells. Untreated (d), Pt-PVP treated (e) and Pt-FA treated (f) MCF7 
cells. Untreated (g), Pt-PVP treated (h) and Pt-FA treated (i) IMR90 cells. 
Concentration of Pt-nps = 100 µg/ml. Yellow arrows point to cellular components 
such as endosomes and lysosomes, while green arrows point to big Pt-nps aggregates. 
 
3.2.2 ATP assay (CellTiter-Glo) – cell proliferation 
A concentration and time-dependent study was conducted to find out the 
effects of Pt-nps on cell viability. Commonly-used cell viability assays are MTT (3-
(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide) or MTS (3-(4,5-
dimethylthiazole-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) which monitor the emission intensity of fluorescent dyes at specific 
wavelengths. A test substance, which might show similar optical properties to these 
dyes, can cause complications during the process of measurement. This is especially 
true when nanomaterials are being tested (Ulukaya, Ozdikicioglu et al. 2008; Doak, 
Griffiths et al. 2009). For example, silver and gold NPs gave distinct UV absorption 
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peaks due to surface plasmon resonance. Therefore, they give false-positive results 
when tested using the MTS or MTT assays.  
The CellTiter-Glo luminescent cell viability assay is designed to monitor 
cytotoxicity as well as cell proliferation by measuring the number of viable cells in 
the culture medium. This assay measures the amount of adenosine triphosphate (ATP) 
present, which is directly proportional to the number of viable cells. One advantage of 
this assay is the short waiting time (minutes) compared to MTS or MTT (four hours 
or more). A comparison between the ATP and MTT assay revealed that the two 
assays gave different results when used to measure growth inhibition of various 
cancer drugs on the lung cancer cell line A549 (Ulukaya, Ozdikicioglu et al. 2008). 
This is because the MTT assay measures the activity of dehydrogenases, while ATP 
concentration was measured in the case of ATP assay. Dying cells lose ATP faster 
than dehydrogenase activity, hence resulting in an over-estimation of cell viability 
when using the MTT assay. Owing to the fact that the ATP assay is more sensitive, it 
was used for our measurement.  
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Figure 3.4: Cell viability assays of HeLa (a, b), MCF7 (c, d), and IMR90 (e, f) 
after exposure to various concentrations of Pt-PVP and Pt-FA 24, 48 and 72 hpt. The 
y-axis represents the percentage of viable cells present in the treated sample after a 
certain time and the x-axis represents the final Pt-nps concentration in culture. The 
values represent the mean ± standard deviation of three independent experiments; * 
denotes P < 0.05 with respect to the control group; 
#
 denotes P < 0.05 between Pt-
PVP and Pt-FA using Student’s t test. 
 
The viability trends of Pt-PVP and Pt-FA treated cells were similar across 
different cell types. Generally, the viability of cells decreased with increasing Pt-nps 
concentration and with increasing exposure time from 24 h to 72 h (Figure 3.4). Pt-
PVP was comparatively non-toxic compared to Pt-FA. Although Pt-PVP was 
internalized by all cell lines as shown by dark field microscopy, the viability of cells 
was not affected until a high dose of 400 µg/ml was introduced, which reduced the 
viability of all cell types to less than 60% after 24 h. Increasing Pt-PVP concentration 
IC50=463 µg/ml 
IC50=406 µg/ml IC50=168 µg/ml 
IC50=445 µg/ml IC50=170 µg/ml 
IC50=263 µg/ml 
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by eight-fold from 25 to 200 µg/ml did not reduce cell viability even after 72 h of 
exposure. On the other hand, Pt-FA is more toxic than Pt-PVP, especially to MCF7 
breast cancer cells. Unlike Pt-PVP, the dose and time-dependency of Pt-FA are 
consistent across all cell types. At a low dose of 25 µg/ml, viability of HeLa, MCF7 
and IMR90 dropped to 65%, 44%, and 43%, respectively, after 24 h, which is 
significantly lower than Pt-PVP. IC50 is defined as the half maximal inhibitory 
concentration of a drug and the values at 24 h were calculated using linear regression. 
If the drug concentration required to inhibit the growth of cells by 50% is low, the 
drug is said to be more effective. The calculated IC50 values correlated well with our 
observations. The inclusion of IMR90 amidst cancer cell lines allows a comparison of 
toxicity with normal cells. Little selectivity towards cancer cell lines over IMR90 was 
observed despite attaching folic acid on the Pt-nps surface. Folic acid was effective in 
directing Pt-nps into HeLa and MCF7 which over-expresses folate receptors as 
compared to NPs capped with PVP. Although IMR90 does not over-express such 
receptors, it was affected by the toxic effects of platinum even at low doses of Pt-FA. 
However, under in vivo conditions, Pt-FA would be expected to deposit preferentially 
at the tumour site due to an enhanced permeability and retention effect (EPR) which 
improves the selectivity (Allen and Cullis 2004; Peer, Karp et al. 2007; Byrne, 
Betancourt et al. 2008). This is an advantage of nanodrug delivery systems as 
compared to conventional molecular cancer therapeutics such as cisplatin, which has a 
low circulation half-life. 
The increase in toxicity of Pt-FA over Pt-PVP could be due to two reasons: (i) 
higher platinum content; and (ii) increased receptor-mediated endocytosis. The 
platinum content of Pt-FA is 18.2% as compared to 12.5% in Pt-PVP. Under slightly 
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 can be converted to Pt
2+
 (Gao, Liang et al. 2008), which is 
believed to be responsible for the toxicity (Asharani, Xinyi et al. 2010). 
Pt
0
 ⇌ Pt2+ + 2e   E° = -1.18 V  
H2O2 + 2H
+
 + 2e ⇌ 2H2O   E° = +1.776 V 
Pt
0
 + H2O2 + 2H
+
 ⇌ Pt2+ + 2H2O  E°cell = +0.596 V 
These E° values (Lide 2000) were measured at standard temperature, pressure and 
concentration with respect to a standard hydrogen electrode, which may not reflect the 
true conditions in a living cell. However, a positive E° value signifies a spontaneous 
reaction. Gao et al. reported the use of FePt@CoS2 yolk-shell nanocrystals as a potent 
agent to kill HeLa cells, where the FePt core was released from the shell and oxidized 
slowly during the process. Pt
2+
 ions can diffuse into the nucleus and mitochondria 
binding to DNA and leading to apoptosis of HeLa cells (Gao, Liang et al. 2007; Gao, 
Liang et al. 2008). 
Folic acid is a low molecular weight vitamin compound (B9) which has been 
shown to be an effective tumour-targeting compound, especially in cancers such as 
breast, lung, kidney, ovarian and epithelial mouth cancers which over-express folate 
receptors (Peer, Karp et al. 2007; Rosenholm, Peuhu et al. 2009; Wiradharma, Zhang 
et al. 2009). Unlike antibodies or hormones-tagged particles which are shuttled to the 
lysosome for destruction, folic acid-tagged carriers are normally retained in an 
endocytic vesicle or released into the cytoplasm as folic acid is essential for cell 
functions (Byrne, Betancourt et al. 2008). Gold nanoparticles with folic acid-linked 
PEG backbone and its efficiency in vitro have been widely reported (Byrne, 
Betancourt et al. 2008; Patra, Verma et al. 2008; Gullotti and Yeo 2009). Various 
other groups also reported the attachment of folic acid to other polymer backbones in 
nanocarriers (Park, Kim et al. 2005; Yoshida, Oide et al. 2006; Bhattacharya, Patra et 
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al. 2007; You, Li et al. 2008; Pan and Feng 2009). A simple but efficient way of 
directly attaching folic acid onto Pt-nps via in situ reduction of hexachloroplatinic 
acid in folic acid solution using sodium borohydride which does not require extensive 
organic synthesis or purification methods was described. The resulting nanoparticles 
were stable in water and cell medium. Also, the inherent toxicity of Pt-nps and the 
slow oxidation into Pt
2+
 ions as the source of anticancer activity have been 
incorporated into the design strategies. In fact, Pt-FA nanoparticles serve as carrier of 
folic acid and as a drug.  
Other factors which can influence nanoparticles toxicity include size (Hussain, 
Hess et al. 2005; Pan, Neuss et al. 2007; Carlson, Hussain et al. 2008), surface area, 
surface functionalities and charge (Carlson, Hussain et al. 2008; Thevenot, Cho et al. 
2008). In general, NPs toxicity was found to increase with decreasing size due to the 
increase in reactive surface area for interaction with biological molecules or 
generation of reactive oxygen species. Waters et al. reported that changes in gene 
expression in murine macrophages correlated better with total surface area of silica 
nanoparticles rather than particle size or concentration (Waters, Masiello et al. 2009). 
Thevenot et al. tested TiO2 nanoparticles with different surface chemistries in various 
murine cell lines and found that NPs containing the amine functional group were 
more toxic than NPs containing hydroxyl and carboxylic acid functional groups due to 
strong interaction with the negatively-charged cell membrane (Thevenot, Cho et al. 
2008). In fact, cationic liposomes are often used to deliver DNA with high 
transfection efficiencies (Torchilin 2006). Pt-FA is bigger (91.3 nm) and negatively-
charged while Pt-PVP (13.5 nm) is smaller and neutral. Therefore, Pt-FA is expected 
to be less toxic than Pt-PVP. However, interaction with folate receptors enables Pt-FA 
to be internalized by cancer cells to exert its toxic effects. 
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3.2.3 Apoptosis assay – mechanism of cell death 
The apoptosis assay was carried out to assess the extent and mode of cell death 
upon exposure to Pt-nps. Stained cells were passed through the flow cytometer and 
the percentage of unstained cells (live cells), cells with red labels (took up the red 
propidium iodide stain, indicating necrosis), cells with green labels (took up the green 
signal from Annexin V-FITC, indicating early apoptosis) and finally cells which were 
dual-stained (late apoptosis), were generated from dot plots.  
 
Figure 3.5: Annexin-V staining of MCF7 and IMR90 treated with 100 µg/ml Pt-
nps solution for 48 h. Cells stained with PI alone are necrotic, whereas cells stained 
with Annexin V-FITC alone represent early apoptosis. Cells at final stages of 
apoptosis take up both stains. 
 
As expected, treatment of MCF7 with Pt-PVP did not change the percentage 
of viable cells and is comparable to our cell viability assay results using same Pt-nps 
concentration (Figure 3.5). Treatment with Pt-FA caused the percentage of live cells 
to drop by 8% and the combined percentage of cells entering late apoptosis and 
necrosis increased by 12%.  
Interestingly, the response of IMR90 is entirely different from MCF7. With 
Pt-PVP, there was no necrosis found in the control and the percentage of apoptotic 
cells observed was higher than the control by 47%. The percentage of early apoptotic 
cells stayed unchanged. However, with Pt-FA, the percentage of live cells decreased 
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drastically to 14% of the total population and cells were found to undergo only 
necrosis. Therefore, the mechanism of uptake of these particles and its subsequent 
processing by IMR90 could be different from MCF7 cells. These results were 
consistent with the findings from Pan et al., where they reported that 1.4 nm Au-nps 
caused necrosis in HeLa cells whereas 1.2 nm Au-nps resulted in cell death by 
apoptosis predominantly, despite both Au-nps having the same surface functionality 
(Pan, Neuss et al. 2007). While apoptosis is usually related to caspase activation 
(Chipuk and Green 2005), calcium overload (Ozaki, Yamashita et al. 2009; Jahani-
Asl, Germain et al. 2010) or induced by death-inducing signals, necrosis is associated 
with loss of lysosomal membrane integrity (Castino, Demoz et al. 2003). The 
mechanism of cell death can be affected by small changes in particle size and 
functional groups found on the surface of NPs. Such factors can have significant 
influence on membrane interaction, membrane damage, compartmentalization and 
processing of NPs after internalization.  
 
3.2.4 Drug (5FU) release studies – kinetics of release of active drug 5FU from Pt-
FA/5FU/PVP and Pt-Gal/5FU/PVP 
Pt-FA/5FU/PVP was spherical with core size in the range of 10–15 nm, while 
Pt-Gal/5FU/PVP was less spherical but with a uniform size of 4 nm (Figure 3.6(a, b)). 
DLS measurements have showed that the mean hydrodynamic diameters were 12.2 
nm and 13.3 nm for Pt-FA/5FU/PVP and Pt-Gal/5FU/PVP, respectively (Figure 3.6(c, 
d)). A similar TEM and DLS indicated that Pt-FA/5FU/PVP was not covered by a 
thick capping agent and hydration layer in solution. A high platinum-to-carbon ratio 
as showed by elemental analysis supported the data (Figure 3.6(g)). On the other 
hand, Pt-Gal/5FU/PVP had a thick capping agent layer and hydration shell when 
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placed in solution. The zeta potential of Pt-FA/5FU/PVP was at -39.2 mV while that 
of Pt-Gal/5FU/PVP was at -34.0 mV (Figure 3.6(e, f)). 
 
Figure 3.6: Characterization of Pt-FA/5FU/PVP and Pt-Gal/5FU/PVP. TEM 
images of Pt-FA/5FU/PVP (a) and Pt-Gal/5FU/PVP (b). Dynamic light scattering 
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histogram of Pt-FA/5FU/PVP (c) and Pt-Gal/5FU/PVP (d). Zeta potential distribution 
of Pt-FA/5FU/PVP (e) and Pt-Gal/5FU/PVP (f). Chemical composition (in wt%) of 
Pt-FA/5FU/PVP and Pt-Gal/5FU/PVP (g). 
 
Pt-FA/5FU/PVP and Pt-Gal/5FU/PVP carried 5-fluorouracil, a 
chemotherapeutic drug, as a capping agent. As 5FU plays an important role in the 
efficacy of Pt-nps against cancer cells, it is important to determine the degree and 
kinetics of release from Pt-nps. Here, we compared the diffusion of 5FU from 3 
samples: 5FU stock solution, Pt-FA/5FU/PVP and Pt-Gal/5FU/PVP at a concentration 
of 1 mg/ml using the dialysis bag method (Cheng, Peng et al. 2009; Wilson, Samanta 
et al. 2010). Pt-nps cannot cross the membrane, while 5FU can easily diffuse out. 5FU 
may be entrapped, encapsulated, adsorbed or chemically attached (Wilson, Samanta et 
al. 2010). In our case, 5FU was expected to be primarily surface-adsorbed and 
possibly entrapped within the nanoparticle core. 
93% of 5FU in 5FU stock solution diffused out of the dialysis membrane and 
reached a steady state 1 h into the study and approached 100% at 8 h (Figure 3.7). 
When bound to Pt-nps, 5FU did not diffuse out of the membrane as fast as in the case 
of 5FU stock solution. Pt-FA/5FU/PVP reached a percentage released value of 25% 
after 1 h and the total amount released after 24 h was only 42%, indicating a slow and 
sustained release which benefits cancer treatment. Pt-Gal/5FU/PVP released 54.5% 
after 1 h and the total amount released after 24 h was 64.2%. A higher percentage of 
5FU was released from Pt-Gal/5FU/PVP because of a larger concentration gradient 
(Pt-Gal/5FU/PVP carried more 5FU than Pt-FA/5FU/PVP as seen in elemental 
analysis). Also, more 5FU could be entrapped within the platinum core of Pt-
FA/5FU/PVP, resulting in a lower overall release. 
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Figure 3.7: Drug release kinetics of 5FU (black), Pt-FA/5FU/PVP (red) and Pt-
Gal/5FU/PVP (blue). The y-axis represents the percentage of 5FU which diffused out 
of the dialysis membrane and the x-axis represents specific time points.  
 
3.2.5 Effects on cell uptake and proliferation using Pt-FA/5FU/PVP and Pt-
Gal/5FU/PVP 
 Pt-FA/5FU/PVP carried 5FU and PVP as additional capping agents which 
were expected to improve the efficacy and water solubility as compared to Pt-FA. We 
wish to test if Pt-FA/5FU/PVP could reduce the toxic effects towards normal cells 
like IMR90. Zebrafish was used as an in vivo liver cancer model (Chapter 4). Pt-
Gal/5FU/PVP was synthesized to target an in vitro cancer model (HepG2, 
hepatocellular carcinoma) and provided the necessary preliminary data. As such, we 
examined the cellular uptake (darkfield microscopy) and viability (ATP assay) in the 
same fashion as Pt-PVP and Pt-FA. 
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 HeLa (Figure 3.8(a, b)), MCF7 (Figure 3.8(c, d)) and IMR90 (Figure 3.8(e, 
f)) were exposed to Pt-FA/5FU/PVP and checked for uptake. In cancer cell lines 
HeLa and MCF7, an increase in number of endosomes and white dots were observed 
in Pt-FA/5FU/PVP treated cells as compared to the untreated control. Pt-nps 
aggregates, however, were not observed as in the case of Pt-FA, which could be due 
to improved solubility and stability provided by PVP. The normal cell line IMR90 
showed lesser uptake towards Pt-FA/5FU/PVP as compared to Pt-FA, which could 
mean reduced toxicity. 
 Pt-Gal/5FU/PVP was tested in the HCC cell line HepG2. Asialoglycoprotein 
receptors are expressed on the surface of liver cells and attaching galactose on Pt-nps 
can increase uptake. Due to the presence of galactose, a large number of endosomes 








Figure 3.8: Darkfield optical images of untreated (a) and Pt-FA/5FU/PVP treated 
(b) HeLa cells. Untreated (c) and Pt-FA/5FU/PVP treated (d) MCF7 cells. Untreated 
(e) and Pt-FA/5FU/PVP treated (f) IMR90 cells. Untreated (g) and Pt-Gal/5FU/PVP 
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treated (h) HepG2 cells. Concentration of Pt-nps = 100 µg/ml. Yellow arrows point to 
cellular components such as endosomes and lysosomes, while red arrows point to 
dead cell debris. 
 
Next, viabilities of HeLa and MCF7 cells were compared against IMR90 to 
check for cancer selectivity of Pt-FA/5FU/PVP. The efficacy of Pt-FA/5FU/PVP was 
also compared against the chemotherapeutic drug 5FU in these cell lines. It is 
important to note that the maximum concentration tested for 5FU was 200 µg/ml, 
while that of Pt-FA/5FU/PVP was 400 µg/ml. 
The viability trends of HeLa and MCF7 were similar when exposed to 5FU. 
HeLa and MCF7 were insensitive to increasing concentrations of 5FU 24 hpt, until a 
high concentration of 100 µg/ml was introduced. The viabilities, however, began to 
drop drastically after 48 h, even at concentrations as low as 10 µg/ml (Figure 3.9(a, 
c)). This is possibly due to low diffusion rates of 5FU in these cells, although 5FU 
was highly potent. The normal cell line IMR90 showed higher viability (Figure 3.9(e)) 
when compared against HeLa and MCF7 cells, which may be because cancer cells are 
fast-dividing, hence higher sensitivity toward cancer drugs. This is the underlying 
principle of chemotherapy. 
 HeLa and MCF7 demonstrated different viabilities when exposed to Pt-
FA/5FU/PVP, with MCF7 being more susceptible to the damages. Previously, Pt-FA 
was also found to reduce cell viability of MCF7 to a greater extent. This may be due 
to HeLa cells expressing lesser folate receptors than MCF7 cells. After 72 h of 
exposure at 400 µg/ml, HeLa cells had a viability of 31.6% but MCF7 had 13.0%. Pt-
FA/5FU/PVP was able to cause more damages to cancer cells because they over-
expressed folate receptors and take up Pt-FA/5FU/PVP via receptor-mediated 
endocytosis. The viability of IMR90 after exposure to Pt-FA/5FU/PVP was similar to 
that of 5FU (Figure 3.9(f)), but the values were improved when compared to Pt-FA 
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(Figure 3.4(f)). The increase in viabilities of IMR90 was supported by reduced uptake 
as shown by darkfield microscopy (Figure 3.8(f)). Overall, Pt-FA/5FU/PVP had the 
same toxicity as 5FU and Pt-FA towards cancer cells, especially MCF7, while 
demonstrating better compatibility towards normal cells. The IC50 of Pt-FA/5FU/PVP 
in IMR90 is calculated to be much higher as compared to Pt-FA and in other cell lines, 
indicating the higher biocompatibility of this nanoparticle. 
As Pt-FA/5FU/PVP showed promising results, Pt-Gal/5FU/PVP was 
synthesized for preliminary in vitro testing using HepG2 before in vivo testing in the 
zebrafish. Pt-Gal/5FU/PVP showed a concentration- and time-dependent toxicity 
towards HepG2 cells, where cell viability decreased with increasing concentration and 
duration of incubation. At a concentration of 25 µg/ml and 24 h of incubation, HepG2 
exhibited a reduction in cell viability and values were significantly different from 
control cells (Figure 3.9(h)). After 72 h, cell viability reduced to 6.5% in presence of 
400 µg/ml Pt-nps. Pt-Gal/5FU/PVP also showed better efficacy than 5FU (Figure 
3.9(g)) at all concentrations tested, proving to be a better nanomedicine than the 
conventional drug.  
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Figure 3.9: Cell viability assays of HeLa (a, b), MCF7 (c, d), IMR90 (e, f) and 
HepG2 (g, h) after exposure to various concentrations of 5FU, Pt-FA/5FU/PVP and 
Pt-Gal/5FU/PVP 24, 48 and 72 hpt. The y-axis represents the percentage of viable 
cells present in the treated sample after a certain time and the x-axis represents the 
final Pt-nps concentration in culture. The values represent the mean ± standard 
deviation of three independent experiments; * denotes P < 0.05 with respect to the 
control group using Student’s t test. 
 
 The uptake of Pt-nps by cell lines and their resulting toxicities are summarized 
in Table 3.10. Using PVP or folic acid as the sole capping agent produced Pt-nps 
which were either non-toxic or too toxic. A combination of both capping agents, 
IC50=311 µg/ml IC50=295 µg/ml 
IC50= N.A IC50=236 µg/ml 
IC50=392 µg/ml IC50=340 µg/ml 
IC50=366 µg/ml IC50=821 µg/ml 
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together with a commercially available cancer drug 5FU produced Pt-FA/5FU/PVP 
which had similar toxicities as Pt-FA in cancer cell lines and low toxicity as Pt-PVP 
in IMR90. As a result of these positive properties, Pt-Gal/5FU/PVP was synthesized 
for in vivo testing in zebrafish with liver cancer. 
  Pt-PVP Pt-FA Pt-FA/5FU/PVP Pt-Gal/5FU/PVP 
HeLa 
Uptake High High High 
Not applicable 
Toxicity Low Medium Low 
MCF7 
Uptake Low High High 
Toxicity Low High Medium 
IMR90 
Uptake Low High Low 












No No Yes 
To be tested in 
zebrafish 
 
Table 3.10: Summary of results for Pt-PVP, Pt-FA, Pt-FA/5FU/PVP,                   
Pt-Gal/5FU/PVP and the cell lines used for in vitro testing. Pt-PVP had low cellular 
uptake and toxicity, while Pt-FA had high uptake and toxicity in both normal and 
cancer cell lines. A combination of capping agents: PVP, FA and 5FU, produced Pt-
nps with high toxicity towards cancer cell lines and low toxicity towards IMR90. The 
targeting ligand was changed from folic acid to galactose to produce Pt-Gal/5FU/PVP 
for testing in zebrafish with liver cancer.  
 
3.3 Conclusions 
PVP and folic acid-capped Pt-nps have been synthesized to evaluate their 
bioactivities in commercial cell lines. The capping agents not only have an effect on 
the stability, shape and size distribution of NPs, but also in the uptake and toxicity of 
NPs by live cells. At 25 µg/ml, viability of HeLa, MCF7 and IMR90 dropped 
significantly to 65%, 44%, and 43%, respectively, after 24 h of incubation with Pt-FA. 
The observed viabilities were >90% in the cases for Pt-PVP. Darkfield optical 
microscope images also revealed increased accumulation of Pt-FA as compared to Pt-
PVP, indicating the effectiveness of folic acid in receptor-mediated endocytosis. Pt-
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nps treatment caused an increase in proportions of MCF7 cells undergoing apoptosis, 
especially in the case of Pt-FA. For IMR90 cells, Pt-PVP treatment caused cells to 
undergo apoptosis, while Pt-FA caused necrosis to take place. This suggests that 
different capping agents caused dissimilar cellular component targeting.  
Because Pt-FA showed toxicity towards both cancer and normal cell lines, Pt-
FA/5FU/PVP was synthesized as an attempt to improve the selectivity towards cancer 
cells and lowering damages towards normal cells. Pt-FA/5FU/PVP showed a 
concentration- and time-dependent relationship with both HeLa and MCF7 which was 
more predictable and comparable to the chemotherapeutic drug 5FU. HeLa and MCF7 
were found to take up more Pt-FA/5FU/PVP from darkfield microscopy images and 
exhibited lower viabilities than IMR90. This subsequently translated into the 
development of Pt-Gal/5FU/PVP for in vivo testing in the zebrafish. 
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As molecular drugs often face challenges from poor water solubility, stability, 
bioavailability and specific targeting, scientists turn to nanotechnology for answers. 
The solution to such issues comes in the form of drug delivery vehicles or even the 
drugs themselves packaged in the “nano” (10-9) size range (i.e. nanomedicine) 
(Moghimi, Hunter et al. 2005). Successful examples which have made it to the market 
include Doxil (doxorubicin encapsulated in 100 nm liposomes), Abraxane (paclitaxel 
bound to 130 nm albumin NPs), Epaxal (liposomes functionalized with influenza 
virus surface proteins) and a few others which have been approved only in recent 
years (Zhang, Gu et al. 2008). Cancer remains one of the most devastating diseases 
with 10 million new cases every year (Peer, Karp et al. 2007). Despite billions of 
dollars had been spent on cancer research for many decades, a permanent cure for 
cancer is not yet achievable. Treatment methods include invasive surgical 
interventions, chemotherapy and radiotherapy which kill surrounding healthy tissues 
together with the tumour. In chemotherapy, a drug or a drug combination is 
introduced intravenously or orally, often accompanied by systemic adverse effects. 
Developing new concepts or strategies may lead to new treatments for cancer and 
reducing side effects by specific site targeting. 
 The enhanced permeability and retention effect (Matsumura and Maeda 1986) 
(EPR) is commonly used in passive targeting of cancers. As tumours have leaky blood 
vessels and poor lymphatic drainage, nanomaterials up to a threshold diameter of 400 
nm can accumulate preferentially in the vicinity of the tumour; while normal blood 
vessels prevent these NMs from building up near healthy cells (Peer, Karp et al. 2007). 
A better and more specialized method to combat cancer cells is active targeting. This 
involves the identification of an over-expressed surface receptor present on the 
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surface of the cancer cells which is not found or expressed in very low levels by 
normal cells. Attaching a targeting moiety, often vitamins, antibodies, nucleic acids 
and carbohydrates on the surface of nanocarriers enhances uptake by cancer cells 
through specific ligand-receptor interactions (Byrne, Betancourt et al. 2008). We have 
discussed the use of folic acid (vitamin B9), acting as both capping agent and targeting 
ligand on the surface of Pt-nps in Chapter 3 (Teow and Valiyaveettil 2011). The folate 
receptor is over-expressed in many types of tumours, including ovarian, breast, lung, 
renal and colon (Dhar, Liu et al. 2008). HeLa (human cervical cancer) and MCF7 
(human breast cancer) cell lines were found to take up folic acid-capped Pt-nps to a 
much greater extent than Pt-nps capped with PVP, a biocompatible, water-soluble,  
synthetic polymer. A more detailed study is necessary to show that this active 
targeting property can also work in vivo. As such, Pt-nps functionalized with 
galactose (active targeting moiety), 5-fluorouracil and PVP (abbreviated as Pt-
Gal/5FU/PVP hereafter) which exhibit both EPR and active targeting effects were 
synthesized for a comprehensive study in the zebrafish. 
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer 
and it is occurring more often worldwide due to the dissemination of hepatitis B and 
C virus infection (Llovet, Burroughs et al. 2003). The tumour is generally treated by 
resection, liver transplantation or percutaneous treatment. With more than 500,000 
new cases being diagnosed yearly and one of the top killers in some parts of Asia, 
HCC is a disease which entails more detailed research (Llovet, Burroughs et al. 2003). 
 Zebrafish (Danio rerio) is a powerful tool for high throughput screening of 
drugs and toxic chemicals (Hill, Teraoka et al. 2005; Asharani, Serina et al. 2008; 
Asharani, Wu et al. 2008; Nelson, Mahmoud et al. 2010). Zebrafish embryos and 
larvae being transparent and small, allow easy observations of the development 
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process using a large population that can be kept in a Petri dish or a 96-well plate. It is 
emerging as one of many promising animal models being used to study human 
cancers. This is because of high degree of similarities in terms of histopathological 
and molecular signatures during tumourigenesis as compared to human (Lam, Wu et 
al. 2006). Zebrafish can develop tumours spontaneously or in response to various 
chemical carcinogens. Transgenesis can be employed for zebrafish to express a 
mammalian oncogene. Exogenous DNA can be introduced by injection into one-cell 
stage embryos. An inducible system can be achieved through the use of an inducible 
promoter such as the Tet-on system. In the presence of the inducer (doxycycline), the 
reverse Tet-controlled transcriptional activator (rtTA) can bind to the Tet-response 
element (TRE) and transactivate the expression of a downstream transgene. An 
inducible Tet-on transgenic line (L-GKR: Liver specific GFP-Kras) has been created, 
which expresses oncogenic Kras specifically in the liver upon induction by 
doxycycline (Chew 2012). Upon induction, heterozygous transgenic fish are 
distinguished from wild-type as they can be screened by their enlarged liver and 
picking out GFP signals in the liver which wild-type zebrafish do not express. 
Aberrant Ras signalling has been implicated in the development and progression of 
human HCC and a high level of kras
v12
 expression could initiate liver tumourigenesis 
(Nguyen, Emelyanov et al. 2011). The design strategy and in vitro efficacy of Pt-
Gal/5FU/PVP was discussed previously in Chapter 3. In this chapter, the in vivo 
efficacies and mechanisms of action of Pt-Gal/5FU/PVP will be studied in the 
zebrafish liver cancer model which over-expressed kras
v12
.  
 In addition to measuring liver size of zebrafish larvae, it is important to 
understand the mechanisms by which Pt-Gal/5FU/PVP exerts its active targeting 
effects due to the presence of galactose. This was achieved by performing 
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ultramicrotomy on Pt-np treated larvae and observation of liver cells under an electron 
microscope. Proliferating cell nuclear antigen (PCNA) staining of liver cells can give 
an indication of the number of proliferating cells before and after Pt-np treatment, 
providing a complementary analysis of the state of the liver. A more elaborate 
approach to monitor uptake by larvae is to attach a fluorescent tag on the surface of 
Pt-nps. As zebrafish larvae are transparent, the movement of fluorescent NPs can be 
observed. Although Pt-nps have a high surface area for attaching bioactive molecules, 
attaching a bulky fluorescent molecule in the presence of many other capping agents 
may be challenging. As such, we have eliminated 5-fluorouracil and PVP in the 
design strategy, while the presence of galactose is still required for active targeting of 
zebrafish liver. From this point on, platinum nanoparticles capped with galactose and 
the fluorescent tag will be referred to as Pt-Gal/Dye.  
Here, we investigated the in vivo effects of Pt-nps in transgenic (Tet-on EGFP-
kras
v12
 and LiPan (Korzh, Pan et al. 2008)) zebrafish larvae using the following 
experimental methods which were described in detail in Chapter 2 (Materials and 
Methods): 
1. Treatment of zebrafish larvae using Pt-Gal/5FU/PVP and imaging of liver 
using fluorescence microscopy. Subsequently, analysis of fluorescence 
images using Adobe Photoshop was performed to calculate liver size 
(pages 40 – 41); 
2. PCNA staining, ultramicrotomy and TEM images of liver (pages 41 – 42); 
3. Tracking uptake of Pt-Gal/5FU/PVP by zebrafish larvae using Pt-Gal/Dye 
(page 34, 41); 
4. Positive (cancer drug 5FU) and negative controls (Pt-nps without 
important capping agents: Pt-5FU/PVP, Pt-5FU/Gal, Pt-Gal/PVP and Pt-
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PVP) were also set up to verify that Pt-Gal/5FU/PVP is the best 
combination of capping agents (pages 33 – 34, 41). 
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Capping agents were carefully selected for their biological interactions in cell 
lines and in zebrafish. Galactose can be used for drug (Wang, Zhang et al. 2010; 
Zaman, Yang et al. 2010; Yang, Meng et al. 2011) and gene delivery (Zanta, Boussif 
et al. 1997; Pun and Davis 2002) as it targets asialoglycoprotein receptors on the 
surface of liver cells. This occurs via receptor-mediated endocytosis of NPs and 
subsequently released from the endosomes (Lai, Lin et al. 2010). PVP is a synthetic 
biocompatible polymer which enhances water solubility and used to modify other 
nanomaterials (Torchilin 2001; Torchilin 2007; Phillips, Gran et al. 2010; Parveen, 
Misra et al. 2012), while 5FU is an antimetabolite showing both in vitro (Borenfreund, 
Babich et al. 1990; Yamamoto, Nagano et al. 2004; Sung and Shuler 2009) and in 
vivo (Ando, Yamashita et al. 1997; Ando, Tanaka et al. 2002; Sakon, Nagano et al. 
2002) effects against HCC. The presence of these capping agents can be confirmed by 
performing a Tollen’s test (for reducing sugars) and determining the concentration of 
fluorine (5FU) in the final product.  
 
4.2.1 Pt-Gal/5FU/PVP treatment and analysis of liver size 
Tet-on EGFP-kras
v12
 zebrafish larvae express GFP in the liver which allows 
convenient measurement of liver size. 25 µg/ml and 50 µg/ml Pt-Gal/5FU/PVP were 
used as higher concentrations (75 µg/ml and 100 µg/ml) resulted in lethality and 
deformities such as bent notochord and tail malformations (Figure 4.1). Indeed, 
throughout the duration of our study, zebrafish larvae did not die or develop physical 
deformities after exposure to Pt-Gal/5FU/PVP (Figure 4.2(a1-d1)). LiPan gave an 
indication of the size of a “normal” liver which allows us to estimate the effectiveness 
of Pt-nps treatment (Korzh, Pan et al. 2008; Chew 2012).  
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Figure 4.1: Brightfield images of Tet-on EGFP-kras
v12
 zebrafish larvae (6 dpf), 
larvae treated with 75 µg/ml Pt-Gal/5FU/PVP (a) and 100 µg/ml Pt-Gal/5FU/PVP (b).  
 
Figure 4.2(a2-c2) showed a representation of the liver size of each treatment 
group. At 4 dpt, the average liver size of 50 larvae reduced by 8.4% and 16.0% for 25 
µg/ml and 50 µg/ml Pt-Gal/5FU/PVP, respectively, as compared to control larvae 
(Figure 4.2(e)). The 50 µg/ml Pt-Gal/5FU/PVP treatment group showed a more 
drastic reduction in liver size and results were similar for both 2 and 4 dpt, indicating 
that Pt-nps concentration could be a more important factor in affecting liver size than 
treatment duration. However, with a longer duration (4 dpt), the average liver size of 
the 50 µg/ml Pt-Gal/5FU/PVP treatment group dropped lower than LiPan (“normal” 
liver size), which may lead to increased toxicity. A careful balance between 
concentration and duration must be obtained. LiPan larvae were also given 25 µg/ml 
and 50 µg/ml Pt-Gal/5FU/PVP in a control experiment. In this experiment, the 
average liver size of larvae in both treatment groups were not significantly different 
from untreated larvae, indicating the effects of Pt-Gal/5FU/PVP were more 
pronounced in rapidly proliferating liver cells, similar to the case of in vitro studies. 
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Figure 4.2: Brightfield images of Tet-on EGFP-kras
v12
 zebrafish larva (8 dpf), 
doxycycline control (a1), larva treated with 25 µg/ml Pt-Gal/5FU/PVP (b1) and 50 
µg/ml Pt-Gal/5FU/PVP (c1), with no difference in physical appearance between each 
group. An image of LiPan zebrafish larva (8 dpf) was also included to give an 
indication of the size of a “normal” liver (d1). Respective GFP and RFP signals were 
imaged and enlarged, clearly indicating that liver size was reduced after exposure to 
increasing concentration of Pt-Gal/5FU/PVP (a2-d2). The average liver size of 50 
larvae in each group was plotted (e), * indicates significant difference from control at 
P < 0.05 using Student’s t test.  
 
4.2.2 PCNA staining, ultramicrotomy and TEM images of liver 
 In order to understand how Pt-Gal/5FU/PVP can affect growth of zebrafish 
larvae’s liver and its mechanisms, proliferating cell nuclear antigen (PCNA) staining 
and TEM analysis of the liver were performed. For PCNA staining, nuclei in cells that 
are in process of proliferating will stain brown, while cells in the resting stage (not 
proliferating) will not be stained. Liver cells in the doxycycline control group 
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displayed intense brown coloration in their nuclei as an indication of proliferation 
(Figure 4.3(a)). In contrast, liver cells of a zebrafish larva treated with 50 µg/ml Pt-
Gal/5FU/PVP displayed faint coloration at 8 dpf, suggesting that Pt-Gal/5FU/PVP 
treatment had caused liver cells to be less active in proliferation. 
 To further demonstrate that a reduction in hepatocyte proliferation was due to 
Pt-Gal/5FU/PVP, ultramicrotomy was performed on the larvae to obtain ultra-thin 
transverse sections of the liver. From the TEM images, endosomes were observed to 
contain black particles which were later confirmed to be Pt-Gal/5FU/PVP via energy-
dispersive X-ray spectroscopy (EDX, Figure 4.3(e-f), black arrows). Black particles 
and EDX peaks belonging to Pt-Gal/5FU/PVP were not observed in the doxycycline 
treated control larva (Figure 4c-d). These evidences showed that Pt-Gal/5FU/PVP 
were indeed taken up by zebrafish larvae via active targeting and resulted in a 
reduction of the liver cell proliferation in our study samples. 
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Figure 4.3: PCNA staining of Tet-on EGFP-kras
v12
 zebrafish larvae (8 dpf), 
doxycycline control (a) and larva treated with 50 µg/ml Pt-Gal/5FU/PVP (b), showing 
reduced cell proliferation in the liver of the Pt-nps-treated larva (20X magnification, 
liver outlined in yellow). TEM (15000X magnification) and EDX analysis of liver 
sections of doxycycline control (c-d) and larva treated with 50 µg/ml Pt-Gal/5FU/PVP 
(e-f), which indicated the presence of Pt-Gal/5FU/PVP in endosomes. Black arrows 
point to endosomes containing Pt-Gal/5FU/PVP, n represents nucleus and c represents 
cytoplasm. 
 
4.2.3 Tracking uptake of Pt-Gal/5FU/PVP by zebrafish larvae using Pt-Gal/Dye 
 As TEM revealed the presence of Pt-Gal/5FU/PVP in the liver, it is interesting 
to study how Pt-nps were taken up by zebrafish larvae. To do this, a nanoparticle 
tagged with a fluorescent dye can be used to track the movement of Pt-nps in the 
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transparent larvae. The fluorescent nanoparticle must retain the active targeting effect 
of Pt-Gal/5FU/PVP, while being fluorescent. As such, Pt-nps using galactose and a 
fluorescent dye (Pt-Gal/Dye) were synthesized. The red fluorescent dye, Alexa Fluor 
594 C5 maleimide was chosen because it exhibits very little spectral overlap with GFP 
signals in the zebrafish liver and can be excited by the 568 nm line of the Ar-Kr laser 
and 594 nm line of the He-Ne laser. Spectrally similar to Texas Red dye, the Alexa 
Fluor 594 dye exhibits bright red fluorescence and have high photostability, enabling 
high contrast against GFP expression in the liver. The thiol-reactive maleimide group 
requires the use of cysteamine as a linker, as it has two functional groups with 
different reactivity. The thiol group (-SH) is required for reacting with the dye while 
the less reactive amine group (-NH2) does not reactive with the dye but only attaches 
to Pt-nps. It is therefore unnecessary to use protecting groups to disguise the amine 
group when cysteamine is reacting with the dye. 
 The synthesis of Pt-Gal/Dye (Figure 4.4(d)) involves 3 steps: (a) synthesis of 
platinum nanoparticles capped with galactose (Pt-Gal); (b) synthesis of cysteamine-
dye conjugate and (c) ligand exchange of cysteamine-dye conjugate with Pt-Gal. The 
synthesis of Pt-Gal/Dye follows a carefully planned strategy in order to avoid 
complications for subsequent steps downstream. For example, cysteamine should not 
be attached to Pt-nps before first forming a conjugate with the fluorescent dye. This is 
because the thiol group on cysteamine can also form bonds with Pt-nps in addition to 
amine group, which makes it impossible to react with the fluorescent dye next. 
 In the initial attempt to synthesize Pt-Gal (Step (a)), sodium borohydride was 
used as the reducing agent for hexachloroplatinic acid in the presence of galactose. 
However, resulting Pt-Gal NPs quickly agglomerated and was not suitable for 
subsequent synthesis steps. This is because sodium borohydride is a strong reducing 
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agent; while galactose with only hydroxyl groups is a weak capping agent. Therefore, 
a slower and weaker reduction method was used for synthesizing Pt-Gal (Figure 
4.4(a)). This involved boiling hexachloroplatinic acid in the presence of galactose. In 
this case, galactose acts as both the reducing agent and the capping agent, forming a 
stable brown solution. For the synthesis of cysteamine-dye conjugate (Step (b)), care 
must be taken to prevent the reaction mixture from being exposed to light as the 
fluorescent dye is light-sensitive. The solution must be stirred under a nitrogen 
atmosphere to prevent thiol groups in cysteamine from oxidation into disulfides by 
molecular oxygen. In Step (c), Pt-Gal/Dye (Figure 4.4(b-d)) was synthesized by 
performing a ligand exchange between Pt-Gal and the cysteamine-dye conjugate. This 
can be carried out by 2 methods: stirring or ultrasonication. Using the stirring method, 
resulting Pt-Gal/Dye grew in size from 5 nm to around 100 nm. However, 
ultrasonication produced Pt-Gal/Dye which was highly aggregated (> 300 nm) and 
therefore unsuitable for biological studies. Hence, biological studies in the zebrafish 
larvae were carried out using Pt-Gal/Dye synthesized from the stirring method. 
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Figure 4.4: TEM image of Pt-Gal (a), Pt-Gal/Dye synthesized by stirring (b) and Pt-
Gal/Dye synthesized by ultrasonication (c). Pt-Gal/Dye is made up of 4 components: 
Pt-np, galactose, cysteamine and the fluorescent dye (d). 
 
To study the uptake of Pt-nps, zebrafish larvae were given Pt-Gal/Dye instead 
of Pt-Gal/5FU/PVP and fluorescence images were taken for the following 4 days of 
exposure. The liver (GFP channel) was outlined in yellow and copied onto both 
brightfield and RFP channels. At 1 dpt (Figure 4.5(a3)), little red fluorescence was 
observed in the pharynx, oesophagus and intestines, indicating that the larva ingested 
very little amounts of Pt-Gal/Dye. From 2 dpt onwards (Figure 4.5(b3-d3)), red 
fluorescence in the intestines was significantly more intense and increasing over time, 
indicating higher Pt-Gal/Dye uptake. The red fluorescence detected in the liver 
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increased over time as well, however, was very faint compared to the intestines. This 
shows that the Pt-nps detected in the liver by TEM was taken up by the larva from 
ingestion. Pt-nps accumulated in the intestines and faint fluorescence was observed in 
the liver from 3 dpt onwards. This could be the reason why liver size was not 
significantly reduced at 2 dpt (Figure 4.2). 
 
Figure 4.5: Fluorescence images of Tet-on EGFP-kras
v12
 zebrafish larvae (4 dpf) 
treated with Pt-Gal/Dye: 1 dpt (a), 2 dpt (b) 3 dpt (c) and 4 dpt (d). The liver’s 
location (GFP) was outlined in yellow and copied onto the brightfield and RFP 
images. 
 
4.2.4 Positive and negative controls 
As 3 different capping agents were used in the synthesis of Pt-nps, additional 
experiments were performed to study how each capping agent could affect the overall 
efficacy of Pt-nps in the zebrafish liver. Four additional Pt-nps were synthesized, each 
lacking one of three capping agents: Pt-5FU/PVP (with capping agents 5FU and PVP), 
Pt-5FU/Gal (with capping agents 5FU and D-galactose), Pt-Gal/PVP (with capping 
agents D-galactose and PVP) and Pt-PVP (with capping agent PVP). The 
chemotherapeutic drug 5FU was also tested. Overall, these Pt-nps lacking essential 
capping agents as well as 5FU were found to be ineffective toward reducing liver 
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proliferation at the same concentrations and treatment duration (Figure 4.6). Average 
liver sizes from these treatment groups were between 92.7% and 104% as compared 
to control larvae.  
5FU is used as a chemotherapeutic drug since 1957 for a wide range of solid 
tumours (Malet-Martino and Martino 2002). However, it is often used together with 
other drugs as its clinical effect is only 10 – 30%. This is because more than 80% of 
the injected dose is rapidly degraded by cytosolic enzymes (Malet-Martino and 
Martino 2002). As the intestines have high concentrations of enzymes for degradation 
of 5FU, it is also not common for 5FU to be administered via the oral route during 
chemotherapy (Malet-Martino and Martino 2002). These could be the reasons for the 
lack of activity of 5FU even though a high concentration (50 µg/ml) was administered 
to the larvae via embryo water (Figure 4.6). Of the Pt-nps (Pt2-Pt5) tested, only the 
larvae treated with Pt2 showed a slight decrease in liver size. This can be attributed to 
the EPR effect and without the presence of galactose for active targeting, the results 
were not statistically-significant. Although Pt3 (with capping agents 5FU and 
galactose) can be expected to show anti-proliferative effects in the liver, the absence 
of PVP had resulted in poor stability of the NPs, which resulted in agglomeration 
during the experiment. Although Pt4 was stable, it lacked the anticancer agent 5FU 
and did not result in a reduction of liver size. Moreover, Pt5 (Pt-PVP) did not show 
significant reduction in liver size. This indicates that platinum nanoparticles acted 
mainly as a delivery vehicle for 5FU, while PVP imparts solubility and stability. The 
presence of galactose was also required to improve upon the EPR effect by active 
targeting of the liver. 
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Figure 4.6: The average liver size of 50 Tet-on EGFP-kras
v12
 zebrafish larvae in each 
treatment group was plotted: 5FU, Pt2 (Pt-5FU/PVP), Pt3 (Pt-5FU/Gal), Pt4 (Pt-Gal/ 
PVP) and Pt5 (Pt-PVP). * indicates significant difference from control at P < 0.05 
using Student’s t test.  
 
 Platinum is commonly employed in nanomedicine in its ionic form (Dhar, Gu 
et al. 2008; Rieter, Pott et al. 2008; Dhar, Daniel et al. 2009). The toxicity of platinum 
ions and their potential as fluorescence imaging agents were previously reported in 
zebrafish (Osterauer, Haus et al. 2009; Osterauer, Fassbender et al. 2011; Wu, Zhu et 
al. 2011). Our group has also reported the toxic effects of poly(vinyl alcohol)-capped 
Pt-nps in zebrafish embryos (Asharani, Yi et al. 2011). This study is the first report of 
functionalized Pt-nps as drug delivery vehicles in zebrafish larvae. Active targeting 
reduced the need for high concentrations of drugs to be used, saving costs, reducing 
side effects and enhances patient compliance. Carefully designed Pt-nps were 
successful in targeting liver of zebrafish larvae, showing potential applications in the 
treatment of human HCC. 
 
4.2.5 Reproducibility and image analysis using ImageJ 
 To verify the efficacy of Pt-Gal/5FU/PVP and its experimental reproducibility 
in zebrafish larvae, the experiment was again performed with the help of other group 
members. Dr. Brahathees synthesized and purified a new batch of Pt-Gal/5FU/PVP 
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and performed the in vivo experiment with the guidance of Mr. Yan Chuan (Prof. 
Gong group). At 4 dpt, Dr. Brahathees captured the fluorescence images of transgenic 
zebrafish larvae and passed them to Mr. Yan Chuan for image analysis using ImageJ. 
ImageJ is a public domain software developed by the National Institute of Health and 
is often used for image processing. The data (Figure 4.7) collected by Dr. Brahathees 
and Mr. Yan Chuan showed significant complementarity to our previous data in terms 
of reproducibility. 
 
Figure 4.7: The average liver size of 20 zebrafish larvae in each treatment group was 
plotted: LiPan (representing “normal” liver), Dox control (representing Tet-on EGFP-
kras
v12
 zebrafish larvae with liver cancer) and Pt-nps (50 µg/ml) (representing Tet-on 
EGFP-kras
v12
 zebrafish larvae treated with 50 µg/ml Pt-Gal/5FU/PVP). The y-axis 
represents the size of zebrafish larvae in pixels (ImageJ) and the x-axis represents the 
different treatment groups.  
 
 Similar to our previous experiments (Figure 4.2(e)), LiPan zebrafish larvae 
act as a reference to indicate whether liver size of Tet-on EGFP-kras
v12
 zebrafish 
larvae has reduced to the “normal” size after drug treatment. Mr. Yan Chuan has 
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generated a dot plot to indicate the spread of liver sizes in each treatment group. From 
his analysis (Figure 4.7), LiPan larvae displayed the lowest average liver size, while 
Tet-on EGFP-kras
v12
 zebrafish larvae showed the highest. After 4 days of exposure to 
Pt-Gal/5FU/PVP (50 µg/ml), five Tet-on EGFP-kras
v12
 zebrafish larvae showed the 
same average liver size as LiPan larvae and the average liver size was significantly 
reduced (Student’s t test) by 29.5% when compared against untreated larvae. However, 
the average liver size of Pt-Gal/5FU/PVP treated Tet-on EGFP-kras
v12
 zebrafish 
larvae was still slightly larger than the average liver size of LiPan larvae. This is 
different from our previous report (Figure 4.2(e)) that the average liver size of Pt-
Gal/5FU/PVP treated Tet-on EGFP-kras
v12
 zebrafish larvae was similar or lower than 
the average liver size of LiPan larvae after 4 days of exposure. This could be due to (i) 
different batches of adult zebrafish used for spawning and (ii) different people 
performing the image analysis. Overall, it was demonstrated that Pt-Gal/5FU/PVP 
treatment can significantly reduce liver size of zebrafish larvae (reproducible). 
 
4.3 Conclusions 
Pt-nps functionalized with galactose, 5FU and PVP were synthesized via a 
simple in situ reduction method. Resulting Pt-Gal/5FU/PVP nanoparticles were stable, 
water-soluble and were characterized. HepG2, a hepatocellular carcinoma cell line 
was found to take up Pt-Gal/5FU/PVP effectively and showed a concentration- and 
time-dependent toxicity in Chapter 3. Cell viability was reduced by increasing 
concentrations of Pt-Gal/5FU/PVP or incubation time and was found to be 
significantly reduced by as little as 25 µg/ml Pt-Gal/5FU/PVP after 24 h of incubation. 
In this chapter, Tet-on EGFP-kras
v12
 zebrafish larvae were used as an animal 
model to further investigate the activity of Pt-Gal/5FU/PVP. This transgenic zebrafish 
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line was used because its liver can be induced to proliferate and express GFP in the 
presence of doxycycline. The effect of Pt-Gal/5FU/PVP on liver size was studied by 
monitoring the GFP expression in the liver. Similar to in vitro studies in HepG2, liver 
size was found to reduce with increasing concentrations of Pt-Gal/5FU/PVP or longer 
incubation period. However, Pt-Gal/5FU/PVP concentration was a more important 
factor in influencing liver size than treatment duration. At 4 dpt, the average liver size 
of 50 larvae was reduced by 8.4% and 16.0% for 25 µg/ml and 50 µg/ml Pt-
Gal/5FU/PVP, respectively, as compared to control larvae. This was due to active 
targeting of liver by Pt-Gal/5FU/PVP and their subsequent uptake into the endosomes 
of hepatocytes, which reduced cell proliferation. Fluorescent Pt-Gal/Dye 
nanoparticles were used to follow uptake in larvae. Pt-Gal/Dye accumulate in the 
intestines over time and faint fluorescence was detected 3 dpt, accounting for the 
weak activity of Pt-Gal/5FU/PVP at 2 dpt. LiPan zebrafish larvae and other Pt-nps 
which lacked essential capping agents acted as negative controls. The controls 
highlighted the importance of all 3 capping agents (galactose, 5FU and PVP) in order 
for Pt-nps to be effective. We emphasized on reproducibility of experiment data 
especially in animal models. The efficacy of newly-synthesized 50 µg/ml Pt-
Gal/5FU/PVP was studied in Tet-on EGFP-kras
v12
 zebrafish larvae by other 
colleagues following the same procedures. Newly-synthesized Pt-Gal/5FU/PVP was 
found to cause significant reduction in liver size of Tet-on EGFP-kras
v12
 zebrafish 
larvae by 29.5% after 4 days of exposure. The image analysis was performed using 
ImageJ, complementing our previous data. Overall, functionalized Pt-nps were an 
effective active targeting agent for liver cancer in zebrafish and showed promise for 























 This study made use of both in vitro and in vivo techniques to explore the use 
of Pt-nps as drug delivery vehicles and to be further developed as a nanomedicine. 
Nanomedicine provides solutions to the flaws of conventional drugs, which includes 
solubility, stability and targeting. Using biocompatible and water-soluble polymers 
like PVP in the construct solved major issues, but the resulting Pt-PVP nanoparticles 
were biocompatible and not an ideal nanomedicine. A careful analysis of in vitro and 
in vivo models reveals that additional capping agents like folic acid/galactose and 5-
fluorouracil which impart active targeting and anticancer effects may be essential to 
synthesize better Pt-nps. 
 After an extensive characterization to study the size, charge, shape and 
elemental composition, Pt-PVP, Pt-FA, Pt-FA/5FU/PVP and Pt-Gal/5FU/PVP were 
tested in cell lines. Darkfield microscopy images showed that cancer cell lines were 
taking up both Pt-PVP and Pt-FA but significantly more in the case of Pt-FA. The 
normal cell line IMR90 also endocytosed Pt-FA, which resulted in toxicity and poor 
viability. The apoptosis assay also revealed the difference in mechanism of cell death 
between cancer and normal cell lines. IMR90 cells were sensitive to the effects of Pt-
nps and could undergo apoptosis after exposure to Pt-PVP and necrosis in the case of 
Pt-FA. MCF7 cells, however, were less sensitive to the effects of Pt-FA at the same 
concentration and could undergo both apoptotic and necrotic pathways. 
As the targeting property of Pt-FA was poor and the sensitivity of normal cell 
lines to Pt-nps toxicity was high, better Pt-nps must be developed. Indeed, combining 
capping agents to form Pt-FA/5FU/PVP has shown that it retained the same 
anticancer effects as Pt-FA in cancer cell lines. Most importantly, IMR90 cells 





Changing the targeting ligand from folic acid to galactose allows Pt-Gal/5FU/PVP to 
target HepG2 HCC cells. It is important to prove that Pt-Gal/5FU/PVP is effective in 
HCC cell line before carrying out tests in the animal model with liver cancer. HepG2 
cells showed high uptake towards Pt-Gal/5FU/PVP, lowering cell viability to a greater 
extent than when exposed to the cancer drug 5FU. 
 Tet-on EGFP-kras
v12
 (liver cancer model) and LiPan (normal liver size) 
zebrafish larvae were exposed to 5FU, Pt-Gal/5FU/PVP and Pt-nps which lacked 
important capping agents to study the effects of these chemicals on liver size. 
Concentrations (≤ 50 µg/ml) were carefully chosen such that the chemicals were non-
toxic towards developing larvae. The livers of LiPan zebrafish larvae were not 
growing as rapidly as Tet-on EGFP-kras
v12
 zebrafish larvae and were therefore less 
susceptible to the effects of Pt-Gal/5FU/PVP. Concentration (25 µg/ml vs. 50 µg/ml) 
of Pt-Gal/5FU/PVP had greater effect towards reducing liver proliferation than 
treatment duration (2 days vs. 4 days). 
 Pt-Gal/Dye demonstrated the increasing accumulation of Pt-nps (red 
fluorescence) in the intestines and liver over 4 days of exposure, which explained the 
greater reduction in liver size with longer durations of treatment. Pt-Gal/5FU/PVP 
was detected in the liver of Tet-on EGFP-kras
v12
 zebrafish larvae using TEM analysis, 
which resulted in the reduction of rate of hepatocytes proliferation, detected using 
PCNA staining. The anticancer drug 5FU and other Pt-nps lacking essential capping 
agents were less effective than Pt-Gal/5FU/PVP in reducing hepatocytes proliferation. 
Overall, Pt-Gal/5FU/PVP is an effective and non-toxic drug for treating HCC in 






5.2 Future works 
 The main focus of our study is to develop nanoparticles for nanomedicine that 
can solve issues posed by conventional drugs in the treatment of cancer. The 
chemicals which were employed may be modified or replaced to further improve 
efficacy: 
1. Platinum was selected because of its reported ability to bind to DNA. The 
anticancer drugs Cisplatin and its analogues and Pt-nps synthesized by 
other research groups made use of the same mechanism. Other heavy 
metals which possess similar properties can also be screened;  
2. Folic acid and galactose are two of many possible active targeting agents. 
Other ligands which may possess specific actions include antibodies, 
aptamers and short peptides which recognize specific receptors over-
expressed or expressed only on tumour cells; 
3. PVP confers stability to Pt-nps in aqueous media and can prolong 
circulation time in the blood. Other polymers which serve the same 
function can also be used, including PEG, poly(cyanoacrylate), poly(D/L-
lactide), poly(lactic acid) and poly(lactide-co-glycolide).  Biopolymers 
from natural sources, such as gelatin and sodium alginate, may provide 
better biocompatibility and easier metabolism for excretion; 
4. 5-Fluorouracil serves as a model anticancer drug for our studies, where 
efficacies of Pt-nps were compared against this drug. Anticancer drugs 
may be used for specific cancers and they may be synthesized in the form 
of nanomedicine to be tested in a suitable cancer model. Alternative drugs 





There are an infinite number of nanoformulations which can be synthesized by 
altering the concentrations of these molecules. Various ratios of capping agents 
should be systematically studied to optimise the therapeutic effect of Pt-nps. 
Tet-on EGFP-kras
v12
 zebrafish larvae can be studied more extensively to 
understand the mechanisms of Pt-nps. Firstly, since zebrafish larvae overexpress Kras 
protein, changes to the amount of protein after exposure to Pt-nps can be quantified. 
Secondly, an apoptosis assay can be performed to determine if Pt-nps result in 
apoptosis of liver cells and other tissues in the larvae. This data could complement the 
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